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1 INTRODUCTION 
 
1.1 Pharmaceutical care 
 
Pharmaceutical care has been defined as ‘the  responsible  provision  of  drug  
therapy  for  the purpose  of  achieving  definite  outcomes  that  improve  the  
patient's  quality  of  life’ [1]. It can be seen as a systematic approach that 
ensures that the patient gets the right medicines, for the right reasons, at the 
right time and in the right dose, so the patient’s drug therapy is as safe and 
effective as possible. Therefore medicine-related problems such as drug 
interactions, receiving of wrong doses, adverse drug effects that could be 
avoided, and drug administration problems need to be identified, resolved and 
prevented. Within that concept the patient needs to be educated so they 
understand and get the desired outcome for each medical condition [2, 3]. ‘Of 
all the healthcare professions, pharmacists have the widest knowledge in the 
science and use of medicines’, but this should not lead to the false conclusion 
that pharmaceutical care is exclusively provided by the pharmacist [2]. 
‘Pharmaceutical care can be delivered in different clinical settings in different 
clinical cultures by different teams of pharmacists, technicians, doctors and 
nurses. Pharmaceutical care can therefore be understood as a quality 
assurance system based on improved teamwork and improved systems for 
providing drug treatment’ [3].  
 
Hudson et al. [3] identified current threats to the quality of medication and 
proposed a systematic approach in pharmaceutical care to improve it: 
 
• ‘Patients’ needs for drug therapy are not always formally assessed or 
agreed with the patient. Medication gets prescribed to solve one 
problem after another. One clinician needs to take an overview, 
sometimes needing to rationalise certain combinations.  
• The goals of medication (for example, target blood pressures) need to 
be made more clear to patients and all members of the health care 
team.  
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• Patient monitoring needs to be improved according to written plans.  
• Documentation  needs  to  be  improved in  the monitoring of long term 
medication and pharmacists can help to document successful 
achievement of target goals as they become more patient oriented.‘ [3] 
 
Mehuys et al [4] identified four main issues of patients with COPD in primary 
care that could be improved: (1) Drug adherence, (2) inhalation technique, (3) 
smoking cessation and (4) influenza vaccination in patients younger than 65 
years. 
 
1.1.1. Pharmaceutical care planning 
 
A pharmaceutical care plan is a tool to identify and record problems with a 
patient’s medicines [3] and to assure that a patient’s therapy is conform as far 
as possible with guidelines. It is a systematic documentation of patients’ 
pharmaceutical care needs and care issues, the desired outcomes and the 
required actions that need to be undertaken to fulfil these outcomes. 
Pharmaceutical care needs can be product or service specific. A product 
specific need is for example the requirement of additional medication, or 
another formulation of the drug. Service specific needs include the 
requirement for additional monitoring or counselling. Potential and actual 
pharmaceutical care issues are generated from a patient’s pharmaceutical 
care needs and the consideration of risk factors such as age, medical history, 
reduced renal clearance, polypharmacy or potential drug toxicity.  
 
The pharmacist can identify and review both, pharmaceutical care needs and 
pharmaceutical care issues, by face to face dialogue with the patient and by 
obtaining information from previous patient records. The next step is to define 
the desired outcomes and consider actions that need to be taken to achieve 
those outcomes. The outcomes and actions have to be agreed with the 
patient and communicated to other involved healthcare professionals. A care 
plan facilitates continuity of care, enables the pharmacist to respond to 
changes in a patient’s needs and allows a comparison of actual outcomes 
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with desired outcomes. It is used as a basis for ongoing review and monitoring 
linked to the patient’s dispense of repeat or serial prescription. An end of care 
treatment summary is generated from the care plan and can be used to 
communicate with the patient’s GP about considered actions to be taken. 
Furthermore each patient receives a tailored action plan, containing specific 
advice for self management of their disease and actions they need to 
undertake themselves [5]. 
 
 
In chapter ‘1.2 Background information on COPD (page five)’, potential care 
issues for patients with COPD have been identified and are summarised in a 
box at the end of each section.  
 
 
1.1.2. Community pharmacists and pharmaceutical care 
 
In Scotland community pharmacists are often a patients’ first point of contact, 
or sometimes even their only regular contact with a healthcare professional 
[2]. The National Institute for Clinical Excellence’s (NICE) COPD guidelines 
propose that management of COPD should be provided by a multidisciplinary 
team [6]. Currently, in advance of a formal role for community pharmacists, 
local schemes are using Prescribing Support Pharmacists (PSPs) to 
undertake medication review. 
 
1.1.3. Medication review clinics 
In Greater Glasgow and Clyde (GGC) the Pharmacy prescribing support Unit 
(PPSU) encompasses all of the staff and work in relation to medicines in a 
single system function. The role of NHS Greater Glasgow and Clyde PPSU is 
to ensure that patients derive maximum benefit and minimum harm from their 
pharmaceuticals and  that medicines are purchased, stored and prescribed as 
cost effectively as possible. As members of PPSU, PSPs are running 
medication review services in community health centres for patients with 
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chronic conditions such as COPD [5]. Patients are targeted with the General 
Practice Administration System for Scotland (GPASS) [7].  
 
The PSP performs a full medication review and as part of it, they arrange an 
appointment for a face-to-face dialogue with the patient. Once the GP 
approved the PSP’s suggestions, submitted by referral, it is the pharmacist’s 
responsibility to ensure that they are carried out. It has been shown by the 
pharmacy team at County Durham and Darlington NHS Foundation Trust that 
PSPs can improve clinical outcomes and quality of life outcomes for patients 
with COPD [8]. Also it has been demonstrated that significant cost savings 
can be made in this patient group [5]. 
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1.2 Background information on COPD 
 
1.2.1 Definition 
 
NHS guidelines [6] define COPD as a progressive, not fully reversible airflow 
obstruction. The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines [9] moreover associates the disease with an abnormal 
inflammatory response of the lungs to noxious particles or gases, 
predominantly tobacco smoke. Airflow limitation can be detected through 
measurement of the forced expiratory volume in one second (FEV1) and the 
FEV1/FEV (forced vital capacity) ratio, which both are decreased [10]. 
 
1.2.2 Epidemiology and economic impact 
 
In 2000 more than 2.7 million people died of COPD worldwide, about 70% of 
them in China and India, and approximately 300,000 in Europe, North 
America and Australia [11]. In industrialised countries smoking of tobacco is 
the major risk factor for developing COPD [10]. In UK 3.7 million people are 
thought to be living with COPD and they are responsible for more than one 
million hospital bed days every year [12, 13]. A remarkable percentage of 
young adults (aged 20-44) already suffer from COPD, the prevalence in this 
age group in UK is 3.3% which is around the average of high income 
countries [14]. Almost 2% of the Scottish population have been diagnosed 
with COPD and 4500 deaths are associated with the disease each year. The 
incidence of COPD is expected to increase by 33% in the next 20 years [12].  
 
1.2.3 Pathology, pathogenesis and pathophysiology 
 
A healthy lung has reached its maximum FEV1 value (about 3.5-5 
litres/second) at the age of 20-25, thereafter a natural slow irreversible decline 
in lung function occurs of around 25ml/second per year in asymptomatic non-
smokers. In smokers accelerated losses of 50ml/second per year or more are 
observed [15].  
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The pathological impairment of lung function is a result of different 
pathological mechanisms that accompany each other and occur combined in 
most patients, such as narrowing of small airways, emphysematous 
destruction of lung parenchyma, tissue remodelling, loss of lung elasticity, 
enlargement of mucus glands and mucus hypersecretion [16, 17]. They are 
caused by both innate and adaptive immune responses [10]. 
 
The physical barrier between airspace and tissue is made up with tight 
junctions between lung epithelial cells. The junctions are disrupted by chronic 
exposure to cigarette smoke and the innate immune response is activated. 
The response leads to phagocytosis procured by different kinds of 
inflammatory cells like polymorphonuclear cells, eosinophils, macrophages, 
natural killer cells and mast cells as well as B- and T- lymphocytes [10].  
 
The innate immune response mechanisms include sputum, mucociliary 
escalator activity and cough. These mechanisms work co-operatively with the 
cells of the immune system to transport particles out of the lungs and maintain 
mucociliary clearance. Furthermore the normal host response to immigration 
of micro-organisms from the upper airways to the usually sterile lung is 
suppressed by chronic cigarette smoke exposure. Smoke exposure therefore 
allows microbes to invade tissue and cause infections [10].   
 
The adaptive immune response takes place inside the lung, either after the 
antigen has been transported through the intact epithelium by specialised, so 
called M-cells or after penetration through injured epithelium. Dendritic cells 
transport antigens into bronchial associated lymphatic tissue and regional 
lymph nodes, where antigen presentation takes place. T- and B-lymphocytes 
are involved and as a result, antibody-producing cells as well as memory cells 
are built. Cytokines like e.g. tumor necrosis factor-alpha (TNFα) and 
interleukin 1β regulate innate and adaptive immune responses and play a 
major role in fever induction [10].  
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Infections of the lower respiratory tract 
Through chronic exposure to particles and gases the immune response 
manifests, the chronic inflammation of central airway’s epithelium results in 
increased cough and sputum production and finally leads to the disruption of 
the epithelial barrier which causes loss of bacterial sterility. Smoking is known 
to increase the amount of leucocytes in lung capillaries due to different 
mechanisms, like stimulation of bone marrow or capillary compression [10]. 
 
Lower respiratory illness occurs more frequently, and the FEV1 loss is 
significantly greater, in COPD patients who are smokers compared to quitters 
[18]. This outcome is supported by reports that have shown that the presence 
of B- and T- Lymphocytes in the airways tissue (especially in the bronchial 
associated lymphatic tissue) results in a decrease in FEV1 [10].   
 
The bronchial associated lymphatic tissue seems to play a major role. In 
smokers and COPD patients its size is depending on the disease’s severity, 
on the contrary in healthy non-smoker almost none of this tissue can be found 
[10]. 
 
Small airways obstruction 
Airways lumen calibre is decreased by accumulation of mucus in the small, 
peripheral airways, swelling of airway walls due to immigration of cells into the 
sub epithelial bronchial associated lymphatic tissue and smooth-muscle 
contraction. Furthermore lumen volume and enlargement during lung inflation 
are restricted by peribronchiolar fibrosis, which is a deposition of connective 
tissue in the adventitial compartment. Additionally number and strength of 
alveoli attachment to the airway’s outer walls declines, which leads to a higher 
FEV1 loss [10].  
 
Emphysema 
Emphysema is a progression of COPD from the over-distension of the lung’s 
air cells with partial destruction of their walls. The rupture and fusion of 
contiguous air-vesicles results in the formation of large sacs and subsequent 
reduced maximum expiratory flow due to limitation of the elastic recoil force 
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that is used for driving the air out of the lungs and holds the airways open in 
expiration [19]. The centrilobular form of emphysema is mostly found in the 
upper lobes of the lung while the panacinar form affects mainly the lower 
lobes. The centrilobular form goes along with more severe small-airway 
obstruction and its appearance correlates with the total overall exposure in 
pack-years to cigarette smoking, although only 40% of even heavy smokers 
develop substantial lung destruction [10]. 
 
In many cases a high amount of lung capacity has been lost decades before 
symptoms like breathlessness appear. The detailed correlation between FEV1 
and occurrence of symptoms in natural history remains unclear [15]. 
 
 
1.2.4 Risk factors  
 
1.2.4.1 Toxic gases and particles 
 
The total burden of toxic gases and particles that individuals inhale during 
their lifetime correlates with the diagnosis of COPD. In tobacco smokers the 
number of pack years is closely related to a decline in FEV1 [20]. Pack years 
are defined as the number of cigarette smoked per day, divided by 20, 
multiplied by the years of consumption [6]. 
 
In industrialised countries smoking of tobacco is the major risk factor for 
developing COPD [10]. The smoking rate in Scotland was 27.2% in 2007 [21]. 
Prevalence rates of COPD in USA population aged >45 are about 35% in 
smokers and 22% in former smokers compared to 8% in non-smokers [22]. A 
study from Sweden reported that approximately fifty percent of elderly 
smokers develop COPD [23]. Around 25-45% of patients with COPD have 
never been smokers [24]. 
 
In cannabis consumers smoking of one joint has the equal effect on airflow 
obstruction as 2.5-5 tobacco cigarettes. While in the study by Aldington et al. 
microemphysema was diagnosed in 18.9% of users of combined cannabis 
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and tobacco but only in 1.3% of users of cannabis alone. Decreased lung 
density was found in high-resolution computer tomography scans of cannabis 
smokers [25]. 
 
Non smoking causes may be prevalent in some developing countries where 
there is higher exposure to smoke from coal and biomass fuel, which is 
generated through cooking and home heating. Some 4-5% of worldwide 
mortality (1.5 million - 2 million deaths in 2000) can be attributed to indoor air 
pollution. Approximately half of these deaths are caused by acute lower 
respiratory infections in childhood and a dominant part of the rest is 
associated with COPD, followed by lung cancer in adult women [26]. 
 
Outdoor pollution is known to cause a range of health problems, including a 
raise in cardiopulmonary deaths and higher incidence of different pulmonary 
diseases. Urban ambient air has been associated with increased prevalence 
of COPD and worsening of existing COPD. Children growing up close to a 
motorway have a lower rate of growth in FEV1, resulting in impaired lung 
function as adults [27]. One study showed that the prevalence of COPD in UK 
postmen from higher polluted areas was higher than those in cities with lower 
pollution. There is a range of other occupations containing an elevated risk for 
developing COPD through exposure to toxic gases, dust or fumes in 
workplaces like farms, factories, mines and construction sites. Some 318 000 
deaths worldwide from COPD were associated to occupational exposure in 
2000 [24].  
 
Pharmaceutical care issues: 
 
• Record smoking status  
• Ask patient about dust or fume exposure 
• Calculate pack years 
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1.2.4.2 Prenatal and childhood events 
 
Premature birth is related with respiratory illness in childhood and birth weight 
correlates with lung function [28]. Smoking during pregnancy, maternal 
hypertension and a family history of asthma lead to reduced respiratory 
function in offspring directly after birth, which is related to wheezing illness 
and asthma, but the potential association with the development of COPD 
remains unclear [29]. The occurrence of chronic bronchitis or pneumonia in 
young children results in a reduced maximal attained lung function in 
adulthood [30] but childhood respiratory illness does not increase the decline 
in FEV1 and FVC later in life [31]. 
 
Maternal smoking during pregnancy and in childhood affects the offspring in 
several different ways: It lowers their lung volume independently from own 
smoking and if children of smoking mothers take up smoking themselves in 
adulthood their smoking intensity is higher and they are more unlikely to quit 
smoking. Personal and maternal smoking increase airflow limitation [32]. 
 
 
1.2.4.3 Genetic factors 
 
Alpha-1 antitrypsin (AAT) deficiency 
Severe alpha-1 antitrypsin (AAT) deficiency is a well known genetic 
predisposition for COPD, although only about 1-2% of COPD patients inherit 
the mutation in the PI Z allele which is the most common deficient variant and 
accountable for the majority of AAT deficiencies [33]. The SZ and ZZ 
genotype in the α1-antitrypsin gene are early disease markers for COPD and 
could be used as biomarkers [34]. AAT is synthesised in the liver and belongs 
to the serine protease inhibitor superfamily. It protects the lungs against the 
elastolytic damage which is mediated by neutrophile elastase. Prevalence of 
neutrophile elastase leads to increased proteolytic activity and therefore to 
emphysema. Moreover AAT deficiency is associated with further disorders 
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such as liver and skin diseases or Wegener’s granulomatosis. The disorder is 
autosomal co-dominant inherited and occurs in 1 of 2000-5000 humans [35].  
 
Most likely there are further genetic determinants, like e.g. variations in the 
Macrophage scavenger receptor 1 (MSR1) gene [36] that influence the 
susceptibility to develop COPD but further studies need to be performed to 
support these hypotheses. 
 
Pharmaceutical care issues: 
 
• Record if patient has a diagnosis of AAT-deficiency 
• Patients with a family history of AAT-deficiency or with young onset 
(aged <40 years) of COPD should be referred to a specialist 
 
 
 
1.2.4.4 Socioeconomic status 
A low socioeconomic status is an independent risk factor for COPD. Reasons 
therefore might be housing conditions, intra-uterine growth retardation and 
poor nutrition [24].  
 
 
1.2.5 Impact of gender 
 
In the EU in average 35% of man smoke compared to 22% of women, and 
two to three times more males die of COPD than females [37]. On the other 
hand it has been proven that female smokers have a faster decrease of FEV1 
[38] and their level of dyspnoea is higher than in males [39]. Especially the 
field of pharmaceutical care is affected by gender related differences: Female 
patients have a lower health related quality of life score [40], one of the 
reasons therefore is that anxiety and depressive symptoms appear more often 
in them [39] and moreover it has been shown that male COPD patients have a 
significantly higher benefit from exercise therapy on health-related quality of 
life [41]. In one comparison of patients women performed poorer in walking 
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distance, even though they had the same FEV1, better oxygenation, better 
PaCO2 and fewer co-morbidities [42]. Gender related differences regarding 
both the burden of disease and the response to its therapy should be kept in 
mind when designing treatment strategies for COPD patients. 
 
 
Pharmaceutical care issues: 
 
• Record patient’s sex 
 
 
1.2.6 Diagnosing 
 
The rate of undiagnosed COPD is rarely measured, but it could be as high as 
12% [43]. Approximately 20% of smokers over the age of 40 have 
undiagnosed COPD, and every third patient older than 40 years diagnosed 
with asthma actually has COPD instead [44]. 
 
1.2.6.1 Symptomatic diagnosis 
Patients often accept their symptoms as a consequence of smoking or a part 
of ageing, which makes them less likely to report their symptoms [45]. In the 
UK NICE guidelines recommend that in patients older than 35 who show 
symptoms like breathlessness, cough, wheeze, frequent respiratory tract 
infections or regular sputum production and have risk factors like smoking, 
spirometry should be performed to substantiate a potential diagnosis of 
COPD. Weight loss, effort intolerance, waking at night, ankle swelling, fatigue 
or existing occupational hazards can support the suspicion. While if chest pain 
or haemoptysis occur another diagnosis should be considered [6]. 
 
NICE guidelines recommend the use of the Medical Research Council (MRC) 
dyspnoea scale to assess the breathlessness. 
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Table 1: MRC dyspnoea scale [6] 
 
Grade Degree of breathlessness related to activities 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own place 
 
4 Stops for breath after walking about 100m or after a few minutes on 
level ground 
 
5 Too breathless to leave the house, or breathless when dressing or 
undressing 
 
 
 
In most cases these symptoms appear many years after the presence of the 
structural and functional changes described in chapter 1.2.3 (page five) [15]. 
 
Pharmaceutical care issues: 
 
• Assess MRC grade  
• If unexpected clinical worsening occurs, the patient should be referred 
to a specialist 
 
 
 
1.2.6.2 Spirometry and classification of severity 
 
Spirometry is a safe, uncomplicated, economical and non-invasive method to 
scan reliably for airflow obstruction. In UK it can be performed by any trained 
health care worker. The most important obtained values for diagnosing COPD 
are FVC and FEV1 [6, 44].  
 
Forced vital capacity (FVC) is defined as the volume of gas that can be 
exhaled during a forced expiration starting from maximal inspiration and 
ending at complete expiration. A loss of 500ml or more within 5 years is 
defined as rapid progress of the disease. These patients should be referred to 
a specialist. The timed forced expiratory volume (FEV1) is defined as the 
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volume of gas that can be exhaled within the first second of the forced vital 
capacity manoeuvre. The European Respiratory Societies (ERS) reference 
values for FEV1 are used to calculate the grade of severity of airflow 
obstruction. Spirometry is performed after application of a bronchodilator [6, 
46].  
 
Table 2: ERS equations for predicting FEV1 [46] 
 
Gender Predicted FEV1 
Male 4.30 · height (m) - 0.029 · age (years) - 2.49 
Female 3.95 · height (m) - 0.025 · age (years) - 2.60 
 
 
 
Table 3: NICE classification of severity of airflow obstruction [6] 
 
Severity  
mild FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
moderate FEV1/FVC < 0.70 
50% ≤ FEV1 < 80% predicted 
severe FEV1/FVC < 0.70 
30% ≤ FEV1 < 50% predicted 
very severe FEV1/FVC < 0.70 
FEV1 < 30% predicted or  
FEV1 < 50% predicted plus respiratory failure 
 
 
As there is a high rate of under diagnosed and misdiagnosed COPD some 
study authors suggest that spirometry screening should broadly be performed 
in high-risk populations. Spirometry allows an early detection, even of 
preclinical conditions and enables an efficient disease management and early 
smoking cessation and consequently a possible reduction of accelerated 
losses in FEV1 [44, 43, 45]. It has been shown that by confronting smokers 
with the results of spirometry in form of their ‘lung age’ (the average age of a 
healthy lung with the same performance in spirometry) they are more likely to 
quit smoking [47]. 
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Peak expiratory flow rate 
Another approach for detecting COPD is by using the peak expiratory flow 
rate (PEFR). PEFR is defined as the maximal flow during a forced expiratory 
vital capacity manoeuvre starting from full inspiration. It is widely used and 
most general practitioners are more familiar with this measurement than with 
the more complex spirometry tests. In an analyses of data from the third 
national health and nutrition survey 90% of patients with COPD could be 
identified by having a PEFR smaller than 80% [46, 48]. 
 
Reversibility testing 
The measurement of changes in FEV1 after application of an inhaled 
bronchodilator used to be a common method for diagnosing COPD and 
distinguish it from asthma. But the results of such an assessment are not 
reproducible in one patient and hardly comparable between patients [49]. The 
previous belief that airways obstruction in COPD is largely irreversible has 
been challenged due to new study results. In the UPLIFT trial a majority of 
patients showed significant improvement in FEV1 in response to 
bronchodilator application [50]. Furthermore there is evidence that a single 
dose of a bronchodilator cannot predict the response to long term treatment, 
as it was primarily thought [49]. However reversibility testing is recommended 
by NICE and GGC guidelines to distinguish COPD from asthma as described 
in chapter 1.2.6.4 (page 17). 
 
 
Pharmaceutical care issues: 
• Record spirometry results 
• Classify severity by spirometry results according to NICE 
• Record reversibility testing results 
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1.2.6.3 Further investigations 
 
Disability in COPD can not only be assessed by airway obstruction, also 
factors like frequency of exacerbations, general health status and exercise 
capacity are important factors. Additional investigations recommended by 
NICE guidelines [6] include a chest radiograph (chest X-ray), a full blood 
count and the calculation of body mass index (BMI) in addition to spirometry 
for every patient. If there is an early onset, a minimal smoking history or a 
family history, scanning for AAT deficiency should be performed. If symptoms 
disproportionate to the spirometric impairment occur, a computerised 
tomography (CT) scan of the thorax should be performed and the transfer 
factor for carbon monoxide (TLCO) should be investigated.  
 
Electrocardiography (ECG), pulse oximetry and echocardiogram should be 
performed to assess cardiac status in patients with cor pulmonale. If purulent 
sputum is persistently present a sputum sample should be cultured [6]. In 
patients who are considered for oxygen therapy pulse oximetry is a non-
invasive method to measure the arterial oxygen saturation (SaO2) without 
taking a blood sample by measuring the characteristic light absorption of 
saturated haemoglobin. An arterial blood gas analysis is used to determine 
amongst others the partial pressure of oxygen in the arterial blood (PaO2) [6, 
51]. The BMI, airflow obstruction, dyspnoea and exercise capacity (BODE) 
index can be calculated by summing up achieved points for BMI, FEV1, 
degree of breathlessness according to MRC dyspnoea scale and covered 
meters in a 6-minute walk test. The BODE index allows an assessment of the 
prognosis: the higher the BODE score, the higher the COPD mortality [6, 52].  
 
 
Pharmaceutical care issues: 
 
• Record chest X-ray results 
• Record weight, height and BMI 
• Record CT scan 
• Calculate BODE index 
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1.2.6.4 Differential diagnosis 
 
In young people with symptoms of COPD and a FEV1/FVC ratio greater than 
0.7 or older people without symptoms of COPD but a FEV1/FVC ratio smaller 
than 0.7 an alternative diagnosis should be considered [6]. One very common 
misdiagnosis is asthma [44]. In many cases asthma can be distinguished from 
COPD by clinical features and history. Many COPD patients are smokers or 
ex-smokers. COPD is associated with chronic productive cough and 
persistent and progressive breathlessness while in asthma cough is 
uncommon and breathlessness varies and is often present during night time. 
In asthma symptoms occur frequently under the age of 35 and show 
significant diurnal or day to day variability, while in COPD there is a later onset 
and variability is uncommon. If uncertainty remains, performance of 
reversibility testing, imaging and serial domiciliary peak measurements as well 
as the investigation of the transfer factor for carbon monoxide can help to 
resolve cases [6]. According to Glasgow NHS (GGC) Guidelines a response 
in FEV1 greater than 15% to inhaled corticosteroids or bronchodilators 
suggests asthma [7], NICE guidelines define a greater than 400ml response 
to a bronchodilator as identification criteria for asthma [6]. 
 
Pharmaceutical care issues: 
 
• If respiratory diagnosis is unclear patient should be referred for 
clarification 
 
 
1.2.7 Management of stable COPD 
According to NICE guidelines management of stable COPD should be 
provided by a multidisciplinary team [6].  
 
1.2.7.1 Smoking cessation 
Both, NICE and GOLD guidelines strongly recommend the reduction of risk 
factors, and thus smoking cessation, as the first intervention. Help to stop 
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smoking should be offered by health care professional at every opportunity. 
Stopping smoking slows down the progression of symptoms and the rate of 
decline in FEV1 [6, 9]. Community pharmacies on the NHS run a smoking 
cessation programme within they provide patients with advice and Nicotine 
Replacement Therapy (NRT) supplies [2]. NHS Health Scotland and the 
Scottish Government published a booklet for smokers who are thinking about 
stopping smoking. ‘How to stop smoking and stay stopped’ recommends a 
careful preparation before the actual Stopping. Preparation starts with making 
a list of reasons for stopping, and only if the person is sure that they really 
want to quit, they should continue with making an action plan. The first point of 
this plan is to set a stopping date. Smoking should be stopped completely 
instead of a gradually reduction. As part of the action plan, the patient decides 
weather they want to use stop smoking medication and if a support 
programme (e.g. from a NHS Board specialist or the NHS Health Scotland’s 
telephone service ‘smokeline’ or its website ‘www.canstopsmoking.com’) 
should be used, which both are highly recommended because they increase 
the success rate. Furthermore the booklet contains hints on how to cope with 
withdrawal symptoms and stress, informs about problems that can occur 
during the first months and explains how to avoid weight gain. Also an 
overview about pharmacological treatment is provided. [53] 
 
According to NICE guidelines the smoking history should be documented for 
every patient with COPD [6]. After an unsuccessful attempt to quit smoking, 
no further attempts should be made within 3 months. It is important to be 
supportive and help the patient understand the reasons for the rebound [37]. 
 
Carbon monoxide (CO) measurements and spirometry 
The CO concentration in a smoker’s breath is about 10 times higher than in a 
non-smoker. Within 1-2 days after the last cigarette the CO level returns to 
normal, which is very rewarding for the person to see. Confronting a subject 
with the results of spirometry demonstrating their impaired lung function can 
increase their motivation to quit [37, 47]. 
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Psychological and behavioural interventions 
All three Individual, group and telephone counselling are more effective than 
no intervention. The success rate can be increased by arranging scheduled 
visits after the quit day with a health care provider. Up to eight follow-up 
meetings after 1, 2, 4 and 8 weeks and 3, 6 and 12 months are recommended 
[37]. 
 
Pharmacological treatment 
The odds ratio for smoking cessation under NRT was 1.8 compared to 
placebo. The combination of a patch combined with another NRT formulation 
is more effective than monotherapy. The antidepressant bupropion is effective 
in people who are motivated to stop and who smoke more than 10 cigarettes 
per day [37]. More than twice as much patients stop smoking when following 
bupropion therapy than with placebo. NICE guidelines recommend bupropion, 
varenicline or NRT combined with a support programme for COPD patients 
[6].  
 
The new drug varenicline is a partial agonist of the α4β2 subtype of the 
neuronal nicotinic receptors. It reduces the withdrawal symptoms, the urge to 
smoke and also the satisfaction from smoking, but there might be psychiatric 
adverse effects. In Phase III studies around 50% of patients following 
varenicline therapy were continuously abstinent for the 12-week period of the 
trial, compared to around 30% of patients who received bupropion [54]. The 
weight-loss drug rimonabant is another new promising approach. It may 
influence the effects of nicotine on neural pathways within the brain. In animal 
experiments it has been shown that the self-administration of nicotine was 
decreased by blockade of the cannabinoid CB1 receptor with rimonabant [37].  
Another interesting approach is the development of nicotine vaccination. The 
active immunisation with a conjugated nicotine derivative results in an 
increased production of antibodies against nicotine. In animal experiments the 
brain nicotine concentration was reduced by 36%, while the plasma 
concentration rose 3- to 6-fold, when nicotine was administered in vaccinated 
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rats [55]. Studies in humans showed that not all smokers achieve high 
antibody levels, but in those who do, significantly higher continuous 
abstinence is found, but further studies need to be done [56]. 
 
Pharmaceutical care issues: 
 
• Record number of previous smoking quit attempts 
• Offer entry to cessation program to smokers 
 
 
 
 
1.2.7.2 Pharmacotherapy of COPD 
 
Guidelines recommend inhaled bronchodilators, theophylline and 
corticosteroids. Antitussive therapy should not be used while mucolytic 
therapy should be considered in patients with chronic sputum production. 
Prophylactic antibiotic therapy is not recommended. Pneumococcal and 
annual influenza vaccination reduce hospitalization rate and pneumonia 
vaccination reduces all cause mortality and are therefore recommended [6]. 
Existing medications can reduce symptoms and the severity and frequency of 
exacerbations but none of them can slow down the diseases progress 
expressed by the decline in lung function [9].  
 
Delivery systems 
Bronchodilator therapy is best administered using a hand-held inhaler device. 
Patient training and assessment of satisfactory technique is necessary and if 
appropriate a spacer device can be used. Spacers should not be cleaned 
more often than once a month because of static that can be built up and 
affects the performance. Nebulisers are meant for patients on maximal 
therapy who are still breathless. Its effectiveness and the patient’s ability to 
use it should be assessed and servicing needs to be provided [6].  
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1.2.7.2.1 Inhaled bronchodilators 
Inhaled agents are preferred to oral because they cause less systemic side 
effects. Two classes of drugs, beta2-agonists and muscarinic antagonists are 
available. They can be sub-divided into short- and long- acting. Also 
combinations of different drug classes are used. Beta2-agonists cause 
bronchodilatation and reduce static and dynamic hyperinflation by acting 
directly on bronchial smooth muscle, while muscarinic antagonists achieve 
these effects by inhibiting bronchoconstrictor effects. Their application does 
not necessarily result in an elevated FEV1, even though clinical benefits like 
improvement in symptoms, elevated exercise capacity, faster symptom relief 
or improved activities of daily living can be seen. [6]. 
 
Short-acting bronchodilators 
Short-acting bronchodilators are recommended for initial use in mild cases 
and as rescue medication. They can reduce breathlessness and exercise 
limitation. Short-acting beta2 agonists (SABAs) like fenoterol, salbutamol and 
terbutaline last for about 6 hours. The duration of action of short-acting 
muscarinic antagonists (SAMAs) ipatropium bromide and oxitropium bromide 
is up to 9 hours. As mucus secretion is mediated by muscarinic receptors as 
well, muscarinic antagonist might have further beneficial effects [6, 9]. 
 
Long-acting bronchodilators 
The long acting beta2 agonists (LABAs) formoterol and salmeterol act for 
around 12 hours. Tiotropium is currently the only long-acting muscarinic 
antagonist (LAMA) with duration of action of more than 24 hours, so it only 
needs to be given once daily [6, 9].  
 
Beta2 agonists have to be used with caution in patients with cardiac problems 
or diabetes (see chapter 1.2.10, page 30). Hyperkalaemia may be caused by 
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beta2 agonist, therefore plasma-potassium concentrations should be 
monitored [57].  
 
 
Pharmaceutical care issues: 
• Monitor blood glucose level  
• Monitor plasma-electrolyte concentrations 
 
 
1.2.7.2.2 Theophylline 
A slow-release formulation of theophylline can be prescribed in patients who 
are unable to inhale bronchodilators, after a trial of short- and long-acting 
bronchodilators or in addition to bronchodilators if the patient is still 
symptomatic. Plasma levels must be monitored and interactions with some 
drugs, like e.g. fluroquinolone or macrolide antibiotics are known. Especially in 
elderly patients theophylline is associated with a higher risk because of the 
increased likelihood of co-mobidities and different pharmacokinetics [6]. 
Pharmaceutical care issues: 
• Use of theophylline should be verified and patient should be on 
therapeutic drug monitoring (TDM) 
 
1.2.7.2.3 Corticosteroids 
The aim of corticosteroid therapy is to reduce exacerbation rates rather than 
improving lung function [6, 58],  but their effect has been considered as 
controversial as the COPD inflammation might be resistant to the anti-
inflammatory effects of corticosteroids due to increased acetylation of the 
glucocorticoid receptor [59]. Patients on high-dose inhaled corticosteroids or 
long term oral corticosteroid therapy have an increased risk of developing 
osteoporosis [6]. The NHS GGC’s ‘Direct Access DXA Service’ (DADS) 
provides assessment of fracture risk (FRAX) including assessment for 
osteoporosis and performance of a dual energy X-ray absorptiometry (DXA 
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scan) to measure bone mineral density [7]. Further adverse events associated 
with corticosteroids are non-fatal pneumonia, cataracts, ocular hypertension 
and open-angle glaucoma [60]. 
 
Inhaled corticosteroids (ICs) 
The use of inhaled corticosteroids alone is not licensed for the treatment of 
COPD in UK [6]. Beclomethasone, budesonide, fluticasone and triamcinolone 
are commonly used inhaled corticosteroids [9]. The combination with a long-
acting beta2 agonist in one inhaler is recommended [6, 58]. Formoterol plus 
budesonide and salmeterol plus fluticasone are available as a combination in 
one inhaler [9]. As corticosteroid treatment is a risk factor for osteoporosis, 
patients who receive 1000mcg beclomethasone (or equivalent) and have 
further risk factors should be considered for osteoporosis screening by DADS 
[7]. 
 
Oral corticosteroids 
Maintenance use of oral corticosteroid therapy in stable COPD is not normally 
recommended, but might be required in patients in the severe stage of the 
disease when it can not be withdrawn after an exacerbation [6]. Commonly 
used drugs are prednisone and methylprenisolone [9]. The dose should be 
kept as low as possible. Patients on oral steroids should be monitored for the 
development of osteoporosis and given prophylaxis. Patients on 5mg/day 
prednisolone (or equivalent) for longer than three months should be referred 
to DADS. Patients older than 65 years should be on prophylactic osteoporosis 
treatment without monitoring. [6]  
 
1.2.7.2.4 Combined therapy 
NICE guidelines [6] recommend a combined therapy in patients who remain 
symptomatic on short acting bronchodilator. If FEV1 is greater than 50% 
predicted, either LAMA or LABA should be added, if FEV1 is smaller than 50% 
predicted either a combined inhaler of LABA and IC (‘{LABA+IC}’) or LABA 
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and LAMA should be added, in case IC are n/a. In patients on regular SAMA 
four times a day SAMA should be replaced with LAMA. In patients who remain 
breathlessness or have exacerbations with an FEV1 greater than 50% 
{LABA+IC}, or LAMA in addition to LABA where IC is not applicable, should 
be considered. In all patients who still remain symptomatic a combination of 
{LABA+IC} and LAMA should be prescribed. 
 
Table 4: Medication scheme generated from NICE Guidelines [6]: 
SABA or SAMA 
 
FEV1 ≥ 50% FEV1 < 50% 
LABA  LAMA   
• {LABA+IC} or 
• LABA+LAMA   
           (if IC n/a) 
LAMA 
• {LABA+IC} or 
• LABA+LAMA   
           (if IC n/a) 
LAMA +  
{LABA+IC} 
LAMA + 
{LABA+IC} 
LAMA + 
{LABA+IC} 
LAMA +   
{LABA+IC} 
Additional: 
• Oral Steroid                                       
• Theophylline                                   
• Mucolytic (carbocistein) 
 
 
Pharmaceutical care issues: 
• Check if NICE therapy schema applies, and if it doesn’t record reasons 
for exclusion of certain drugs 
• If patient’s symptom control is inadequate, more medication should be 
added 
• Patients on regular SAMA ≥ 4/d should be switched to LAMA 
• Verify choice of delivery system 
• Assess if nebuliser therapy or spacer is applicable 
• Assess patient’s inhaler and/or nebuliser technique  
• Patients with chronic sputum production should be on carbocistein 
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• Record pneumonia and influenza vaccination status 
• Record DXA scans 
• Discuss possible adverse effects from steroids with the patient 
• Patients on high dose inhaled steroids (≥1000 mcg beclometasone or 
equivalent) and have further risk factors for osteoporosis should be 
referred to DADS 
• Patients on ≥ 5mg/day prednisolone (or equivalent) for longer than 
three months should be referred to DADS. 
• Patients older than 65 on oral Steroids should be on prophylactic 
osteoporosis  treatment, without monitoring 
• Check for unmet preventive medication (CV risk, osteoporosis, 
vaccinations) 
 
 
1.2.7.3 Oxygen therapy 
 
Long term oxygen therapy (LTOT) 
The need for LTOT should be assessed by blood gas analyses and pulse 
oximetry in COPD patients with moderate and severe airflow obstruction 
(FEV1 < 49%), polycythaemia, a raised jugular venous pressure, cyanosis, 
oxygen saturation less than 92% breathing air or peripheral oedema. LTOT is 
indicated in stable COPD patients with PaO2 less than 7.3 kPa or less than 8 
kPa if there is nocturnal hypoxemia (SaO2 < 90% for more than 30% of time), 
peripheral oedema, secondary polycythaemia or pulmonary hypertension. 
Inappropriate use of oxygen therapy can cause respiratory depression. 
Patients should be warned about the risks of fire and explosion if they 
continue smoking. Patients who apply for LTOT should breathe the 
supplemental oxygen as much as possible, 20 hours per day showed greater 
benefits than 15 hours [6].  
 
 
Pharmaceutical care issues: 
• Record LTOT assessments (including PaO2 and SaO2) 
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• Assess if patients not on LTOT should be referred for LTOT 
assessment 
• Assess if LTOT is used a sufficient amount of hours (>15) per day 
 
 
1.2.7.4 Further interventions 
 
Physiotherapy 
Patients with excessive sputum production should be taught the use of 
positive expiratory pressure masks and active cycle of breathing techniques 
[6]. Pulmonary rehabilitation is an individually tailored care programme for 
COPD patients to optimize the patient’s autonomy and social and physical 
performance delivered by a multidisciplinary team. The programme contains 
physical training, disease education and nutritional, behavioural and 
psychological intervention. All patients with a MRC grade greater than two 
should attend pulmonary rehabilitation, however if the patient is unable to walk 
or has unstable angina or has had a recent myocardial infarction the 
programme is not suitable. [6, 7] 
 
Nutritional factors 
The normal range of BMI is between 20 and 25. As COPD patients with a low 
body mass index have poorer prognosis and higher mortality, referral to 
dietetic advice and nutritional supplements combined with exercise 
encouragement might be necessary [6, 61].  
 
Lung surgery 
In patients with a single large bulla a bullectomy, in patients with upper lobe 
predominant emphysema a lunge volume reduction should be considered. 
Patients with homogeneously distributed emphysema can benefit from lung 
transplantation [6]. 
 
Patient education 
NICE guidelines [6] recommend a comprehensive education for each patient, 
including topics like: 
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• Smoking cessation 
• Education about COPD (anatomy, pathology and pharmacology, 
oxygen therapy and vaccinations) 
 
• Anxiety management 
• Symptom and dyspnoea management, including relaxation and chest 
clearance techniques 
 
• Exacerbation management (including when to seek help, self-
management and decision making, coping with setbacks and relapses) 
 
• Nutritional advice 
• Identifying and changing beliefs about exercise and health related 
behaviours 
 
• List of local support groups  
• Information about social services like home care support 
 
 
Palliative care 
In patients with end-stage COPD which is unresponsive to medical therapy 
opioids, benzodiazepines, major tranquillisers, tricyclic antidepressants and 
oxygen can be used to palliate breathlessness [6]. 
 
Social services 
The need for occupational therapy should be assessed by asking the patient 
about their ability to undertake activities of daily living. Patients disabled by 
COPD should be referred to home care support service [6]. 
 
 
Pharmaceutical care issues: 
• Record if patient is pregnant 
 
• Record previous attendance in pulmonary rehabilitation or any other 
secondary care services 
 
• Patients with MRC≥3 should be referred for pulmonary rehabilitation 
• Patients with abnormal BMI should be referred for dietetic 
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advice/nutrition support; If BMI is low give nutritional supplements 
• Record if patient had lung surgery 
• Find out about patient knowledge about COPD and educate if 
necessary 
 
• Patients with clinical failure after all treatment options should be 
referred to a specialist to assess the need for palliative care 
 
• Record patient’s social circumstances (patient: Lives alone, is 
housebound, has professional carer, is in family care) 
 
• Patients who are not coping at home should be referred for home care 
support 
 
 
 
 
1.2.8 Management of exacerbations  
 
An exacerbation is defined as a sustained worsening of the patient’s 
symptoms from their usual stable state which is beyond normal day-to-day 
variations, sustains for at least a day, and is acute in onset. Cough, worsening 
breathlessness, increased sputum production and change in sputum colour 
are commonly reported symptoms. The diagnosis of an exacerbation is made 
clinically and does not depend on the results of investigations [6]. Treatment 
includes the step up of current SABA and adding of 30mg/day prednisolone 
for 7-14 days. In case of purulent sputum the antibiotics amoxicillin or 
clarithromycin are initiated [7]. In severe cases additional intravenous 
theophylline and oxygen therapy are necessary. In patient requiring frequent 
courses of oral corticosteroids osteoporosis prophylaxis should be considered 
[6].  
 
Self management 
Patients at risk of exacerbations should be given a course of oral 
corticosteroids and antibiotics to response promptly to symptoms of an 
exacerbation by self-initiation.  A self management plan should be tailored for 
these patients [6]. 
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Pharmaceutical care issues: 
• Record if patient is on disease self-management plan 
• Assess if patient on self-management plan requires support or revision  
• Record number of exacerbations requiring antibiotics or oral 
corticosteroids in past year 
 
 
 
 
1.2.9 Emerging therapy  
 
Improvement of long acting inhaled bronchodilators 
Researchers are currently working on the improvement of long acting inhaled 
bronchodilators. The new β2-agonists carmoterol and indacaterol and the 
long-acting inhaled muscarinic antagonists aclidinium bromide and 
glycopyrrolate have to be applicated once daily only. New combinations of β2 
agonists and muscarinic antagonists are in development, as well as single 
molecules that link a beta agonist with a muscarinic antagonist. [59] 
 
Antibodies and inhibitors 
While trials with blocking of inflammation mediators like leukotrien or TNFα 
have not been very promising, antibodies against chemokines involved in the 
inflammation process like CXC ligand 8 as well as blocking of their receptors 
have shown inhibition of lung inflammation. Another new promising approach 
is anti-inflammatory treatment with inhibitors of the enzymes Nuclear Factor 
κB, phosphodiesterase 4, phosphoinositide-3-kinase-γ and p38 
mitogenactivated protein kinase but their clinical practice might be limited by 
side effects. [59] 
 
Vitamin D and respiratory health 
In a recent UK study it has been observed recently that the vitamin D status in 
winter of patients with COPD is below the average. It has been shown that 
vitamin D can inhibit TNF-α and enhance IL-10 in immune cells from healthy 
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individuals, the potentially beneficial effects of 1, 25(OH)2D3 on the function of 
airway epithelial cells are currently explored.  [62] 
 
Reversing corticosteroid resistance 
As the inflammation in COPD patient’s lungs might be corticosteroid resistant, 
the probably most promising finding is the reversing of this resistance by 
increasing histone deacetylase-2 activity through theophylline-like drugs, 
nonantibiotic macrolide agents and more effective antioxidants. [59] 
 
 
1.2.10 Co-morbidities 
 
The diagnosis of COPD is associated with multiple co-morbidities and almost 
70% of patients report the appearance of at least one [27]. According to data 
from the UK General Practice Research Database the most common within 
the first year after COPD diagnosis are angina occurring in 4% of incident 
COPD patients followed by cataracts, bone fractures, osteoporosis, 
pneumonia and respiratory infections. There is vastly increased risk for the 
occurrence of various illnesses compared to non COPD patients. Relative risk 
values are: 16.0 for pneumonia, 3.1 for osteoporosis, 2.2 for respiratory 
infection, 1.7 for myocardial infarction, 1.7 for angina, 1.6 for fractures and 1.3 
for glaucoma [63]. Beside respiratory failure the two major causes of death of 
patients with end-stage COPD are lung cancer and cardiovascular diseases. 
The mechanisms for developing each of these conditions seem to be linked 
with each other and might be attributed to the presence of abnormal 
inflammations in COPD. Furthermore smoking is clearly associated with all 
three of them [64] and osteoporosis, glaucoma and cataracts might be caused 
by the corticosteroid therapy of COPD [60]. 
 
COPD and asthma 
In UK 43% of patients with COPD also have a reported history of asthma [63], 
but this high prevalence might be caused by a prior misdiagnosis of the 
patient, because a study shows that one third of patients over the age of 40 
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diagnosed with asthma actually has COPD instead [44]. The clinical features 
differentiating COPD and asthma are described in chapter 1.2.6.4 (page 17). 
 
COPD and cardiovascular diseases (CVD) 
British National Formulary (BNF) recommends avoiding β-Adrenoreceptor 
blockers in patients with heart failure, angina pectoris, myocardial infarction, 
cardiac arrhythmia and hypertension if there is a history of asthma or 
bronchospasm because although some of the β-blockers are cardio selective, 
none of them is cardio specific and lung’s β2-receptors blockade can lead to 
bronchospasm as a side effect. However a cardio selective β-Adrenoreceptor 
blocker can be used under specialist supervision if there is no alternative [57]. 
Since in a meta-analysis in 2002 no significant pulmonary adverse effects in 
patients with mild to moderate COPD secondary to a cardiovascular disease 
were found, the use of cardio selective β-blockers or β1-blockers is strongly 
suggested by the study authors [65].  
 
In Scotland almost one fourth of heart failure patients also have COPD, 18% 
of them receive β-blockers, compared to 41% of heart failure patients without 
COPD. It was found that heart failure patients who also had COPD are more 
frequently treated with loop diuretics and calcium channel blockers in Scotland 
[66]. The use of digoxin in those patients may reduce lung function whereas 
angiotensin-converting enzyme (ACE) inhibitors, Angiotensin-II receptor 
blockers and spironolactone might have beneficial effects on pulmonary 
inflammation, obstruction and gas diffusion [67].  
β2-adrenoreceptor agonists, which are the most commonly used COPD 
treatment, are not completely selective, so myocardial β1-adrenoreceptors 
may also be stimulated which leads to increased mortality in patients with left 
ventricular dysfunction [67]. BNF recommends the use of β2-adrenoreceptor 
agonists in patients with CVD, hypertension or arrhythmias with caution [57]. 
Inhaled β2-adrenoreceptor agonists are prescribed to 57% of patients with 
heart failure and COPD in Scotland [66].  
 
In patients with severe COPD (oxygen or steroid dependent or dyspnoea at 
rest) warfarin dose has to be decreased by 33% [68]. 
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Pharmaceutical care issues: 
• Record co-morbidities 
• Record Blood Pressure (BP) 
• Measure BP 
• Record blood lipids 
• COPD patients on β-blocker should be under specialist supervision 
• Patients with CVD, hypertension or arrhythmias who receive β-
agonists should be under specialist supervision  
• Patients on warfarin need special precaution 
 
 
Pulmonary hypertension and cor pulmonale 
NICE guidelines highlight the possibility of development of pulmonary 
hypertension secondary to COPD because of hypoxic vasoconstriction and 
structural changes. Years of presence of pulmonary hypertension can lead to 
changes in the rights heart ventricle’s function and structure which is defined 
as the clinical syndrome of cor pulmonale. It is characterized by raised venous 
pressure, peripheral oedema and fluid retention. As this condition is caused 
by hypoxia LTOT is recommended for these patients. Oedema should be 
treated with diuretic therapy. ACE inhibitors, alpha-blockers, calcium channel 
blockers and Digoxin are not recommended since there are not enough 
studies to support their benefit [6]. 
 
Pharmaceutical care issues: 
• Patients with presence of peripheral oedema (ankle swelling) should 
be on diuretics 
 
 
 
Anxiety and depression are widespread among COPD patients. In stable 
COPD prevalence rates up to 19% for anxiety and 42% for depression were 
found. The incidence of depression in patients who depend on oxygen 
therapy is even 62%. Two thirds of depressive COPD patients suffer from 
moderate-severe depression. A quarter of COPD patients are assumed to 
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have unrecognized subclinical depression, and less than one third of patients 
receive appropriate treatment. Incomplete treatment is associated with 
increased frequency and prolonged length of hospitalisation, impaired 
treatment adherence, poor quality of life and premature death [69]. Hypoxic 
patients, patients with severe dyspnoea or patients who have been to hospital 
due to an exacerbation have increased risk for anxiety or depression, and 
their mental wellbeing should therefore be assessed by a validated 
assessment tool [6].  
 
The Hospital Anxiety and Depression Scale (HADS) is a self rating 
questionnaire designed to measure the severity of states of depression and 
anxiety in patients under medical treatment. The first half of the items (HADS-
D) measures mostly depression, the second half (HADS-A) measures anxiety. 
Scores range from 0 to 21 for each subscale, scores greater than seven imply 
‘possible’ depression/anxiety, scores greater than ten imply ‘probable’ 
depression/anxiety disorder. The HADS-D can identify patients who may 
benefit from antidepressant drugs [70]. Pharmacotherapy should be offered 
and explained to anxious or depressed patients [6]. 
 
Pharmaceutical care issues: 
• Record previous HADS scores 
• Assess HADS score  
• Discuss management of anxiety and depression in patients with 
HADS-D or HADS-A ≥8 
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2 AIM, OBJECTIVES and SETTING 
 
2.1. Aim  
To design the documentation of a patient profile that includes the identification 
and assessment of pharmaceutical care issues in patients with COPD. 
 
2.2. Objectives 
1. To review the literature in order to define the pharmaceutical care issues of 
patients with COPD and to define a model of pharmaceutical care 
provision within a multidisciplinary team setting. 
 
2. Identify necessary fields of data for inclusion in a pharmaceutical care plan 
for COPD patients and design the documentation based on a previous 
template of a care plan. 
 
3. Field test the design formats for the care plan by conducting a survey of a 
case series. 
 
4. Present findings to clinical pharmacist practitioners to obtain feedback 
from which a final design will be validated. 
 
5. Propose future research to help introduce systematic care provision and 
documentation into the delivery of pharmaceutical care to COPD patients. 
 
2.3. Setting 
The work would fit into a programme of service developments involving 
community pharmacists in services in primary care which aim to reduce 
hospital admission rates.  
In Greater Glasgow and Clyde Prescribing Support Pharmacists (PSPs) and  
COPD Support Pharmacists are running medication review services in 
community health centres for patients with COPD. Patients with moderate 
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airflow obstruction (according to NICE classification) and patients who are 
prescribed bronchodilator therapy are targeted by their GPASS read codes. A 
full medication review is performed and as part of it, an appointment for a 
face-to-face dialogue with the patient, either in the clinic or for a house visit in 
patients with a further progressed stage of disease is arranged. Around six 
patients per day are seen by the pharmacist. Approximately two hours are 
required in the morning to prepare for the patients before the first 
appointment. GPASS is used to obtain patient records.  
 
One patient’s face-to-face dialogue lasts on average half an hour and includes 
assessment of inhaler technique, smoking status and MRC grade as well as a 
measurement of BP. Each patient is asked to bring all of their medicines with 
them and explain when and how often they take it. Smokers are given a brief 
advice to stop smoking. In patients with suspicion of anxiety or depression 
HADSs are assessed and in case of a positive result, pharmacotherapy is 
discussed with the patient. Patients are asked about their knowledge about 
their condition and are educated if necessary. The presence of oedema is 
checked by asking the patient about ankle swelling. The obtained information 
also covers the annual review the NICE guideline [6] demands in patients with 
COPD, which includes recording of smoking and immunisation status, 
assessment of MRC grade and identification of psychological and social co-
morbidity.  
 
After the patient’s appointment a summarised report is inputted into GPASS 
and a referral for the GP containing the PSP’s recommendations is written. 
Once the GP has approved all changes to the treatment plan, the pharmacist 
then prints off prescriptions, sends off referrals and sends a letter or phones 
the patient informing them about actions. It is up to the PSP to ensure that all 
recommendations are carried out and followed up as necessary. 
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3. METHODS 
 
3.1. Literature review and identification of pharmaceutical care issues 
 
Literature review was performed to provide background information on 
pharmaceutical care, to define a model of pharmaceutical care provision 
within a multidisciplinary team setting for patients with COPD, to provide 
background information on COPD and to identify potential pharmaceutical 
care issues in patients with COPD.  
 
The sources include reports on pharmaceutical care by the Scottish 
Government [2, 5], NICE guidelines on COPD [6], guidelines by the Global 
Initiative for COPD (GOLD) [9], the NHS Greater Glasgow and Clyde’s 
‘Primary care COPD Guideline’ [7] and the British National Formulary (BNF) 
[57] as well as systematic reviews, reports and papers. 
 
Therefore the database Pubmed was browsed with the following terms:  
 
• Chronic obstructive pulmonary disease 
• Co-morbidities in chronic obstructive pulmonary disease 
• Depression and Anxiety and chronic obstructive pulmonary disease 
• Detecting markers of chronic obstructive pulmonary disease 
• Diagnosis of chronic obstructive pulmonary disease 
• Emerging therapy in chronic obstructive pulmonary disease 
• Epidemiology of chronic obstructive pulmonary disease 
• Gender in chronic obstructive pulmonary disease 
• Genetic factors in chronic obstructive pulmonary disease 
• Hospital Anxiety and Depression Scale 
• Management of chronic obstructive pulmonary disease 
• Natural history of chronic obstructive pulmonary disease 
• Non-smoking causes for chronic obstructive pulmonary disease 
• Pharmaceutical care 
• Pharmaceutical care planning 
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• Pharmaceutical care in patients with chronic obstructive pulmonary 
disease 
 
• Risk factors for chronic obstructive pulmonary disease 
• Smoking cessation 
• Therapy of  chronic obstructive pulmonary disease 
• Vitamin D and respiratory health 
 
Articles in English language written within the last 35 years have been 
considered. Information on health care services were obtained by web pages 
of the Scottish government (section: Health and Community Care), of the NHS 
and Scotland's Health On the Web (SHOW). During literature research and 
compiling of the introduction on background information on COPD, 57 
pharmaceutical care issues were identified and summarised in a box at the 
end of each section. In June 2010 new NICE guidelines for COPD were 
issued. Subsequent the introduction of this report as well as the identified care 
issues were revised and new care issues were identified.  
 
3.2. Identification of necessary fields of data for inclusion in a care 
plan 
 
All pharmaceutical care issues that had been identified during literature 
research were regarded as necessary for inclusion in a pharmaceutical care 
plan. A transformation of identified pharmaceutical care issues into fields of 
data for a pharmaceutical care plan was performed. The majority of data fields 
of an existing respiratory review form for patients with COPD (F-RR) obtained 
from the first visit in a COPD medication review clinic, and some of the data 
fields contained in an existing care plan for patients with long term conditions 
(CP-LTC) were considered as necessary fields of data for inclusion in a 
pharmaceutical care plan. A list of suggestions for improvement of F-RR by 
COPD Support Pharmacist Joanna Johnson was taken into consideration. 
Anyway data fields from different sources were partly overlapping. F-RR, the 
list of suggestions and CP-LTC can be found in Appendix I. 
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3.3. Designing and revising the pharmaceutical care plan 
 
An existing pharmaceutical care plan for patients with long term conditions 
(CP-LTC) created with Microsoft word by Ejim Chukwuka Ejim [71] was 
revised and several data fields were replaced. The CP-LTC was expanded to 
be more specifically focussed on COPD. The Microsoft Word template of CP-
LTC was maintained. All identified fields of data for inclusion in a 
pharmaceutical care plan were added to CP-LTC in green font colour to obtain 
a care plan for patients with COPD, CP-COPD-1. CP-COPD-1 was field 
tested by the researcher in a medication review clinic and then revised. During 
field testing new care issues have been identified, and moreover in June 2010 
new NICE guidelines for COPD were issued. Identified improvements, newly 
identified care issues and new guidelines were implemented into CP-COPD-1 
in green font colour to obtain a second version of the care plan CP-COPD-2. 
Changes were discussed with the research group and then another survey of 
case series was conducted by the researcher with CP-COPD-2. As no more 
improvements were found, CP-COPD-2 was sent to two Pharmacists to obtain 
feedback. Their feedback and suggested changes were discussed with Dr. 
Julienne Johnson and agreed changes were implemented to obtain the third 
version of a care plan, CP-COPD-3. All versions of the pharmaceutical care 
plan can be found in Appendix I. 
 
3.4. Clinic sit-ins and home visit 
A full police clearance certificate about the researcher stating that there are no 
adverse records was provided to enable access to NHS facilities and patients. 
Dr. Julienne Johnson assisted the researcher by contacting COPD Support 
Pharmacist Joanna Johnson. Initially a request was sent to Richard Lowrie, 
the clinical services lead of the community pharmacy development team in 
NHS Greater Glasgow and Clyde. Richard Lowrie identified COPD Support 
Pharmacist Joanna Johnson as collaborator. A first appointment with Joanna 
Johnson was made by the researcher.  
The first sit-in on 24.05.2010 at Govan Health Centre with Joanna Johnson 
was used to obtain general knowledge about how COPD clinics are run, and 
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to receive a copy of documentation (F-RR), which is currently used by 
pharmacists for COPD medication reviews as well as a list of suggestions for 
improvement. 
Joanna Johnson then arranged an opportunity for the researcher to shadow 
home visits of patients with PSP Lynn Alexander on 22.06.2010, starting from 
Carolside Medical Centre. This second visit was used to field test CP-COPD-1 
on five patients with COPD.  
The third sit-in visit on 12.07.2010 at Govan Health Centre with Joanna 
Johnson was used to field test CP-COPD-2 on four patients with COPD. No 
more improvements for CP-COPD-2 were found. 
 
 
3.5. Feedback by PSPs 
 
A pdf file of CP-COPD-2 in black and white colour was created and sent to the 
pharmacists Lynn Alexander and Joanna Johnson on 17.07.2010 by email 
(Appendix II). Both agreed to try out the care plan at the medication review 
clinics for patients with COPD they were running in their surgeries, Lynn 
Alexander on 23.07.2010, Joanna Johnson on 26.07.2010. On 28.07.2010 the 
pharmacists sent an email containing their feedback to the researcher (see 
Appendix II). The suggested changes were discussed with the research group 
on 03.08.2010. The feedback by both pharmacists was summarised and 
commented in a table. 
 
 
3.6. Final design 
 
Suggestions found useful by the researcher and the research group were 
implemented into CP-COPD-2 to obtain the final design of the pharmaceutical 
care plan for patients with COPD, CP-COPD-3. 
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4. RESULTS 
 
All drafts of pharmaceutical care plans, CP-COPD-1, CP-COPD-2 as well as 
the final version of the pharmaceutical care plan for COPD, CP-COPD-3 can 
be found in Appendix I. 
 
4.1. Analysis of CP-LTC 
 
The design of a care plan for long term conditions, CP-LTC was maintained 
for the development of the COPD care plan. The template was categorised in 
eight sections: 
 
1. Personal data 
Personal data include name, reference number, address, date of birth (DoB), 
sex, body weight, height, BMI, smoking status and social circumstances. 
 
2. Monitoring data 
This section contains fields of data for the record of basic lab parameters such 
as blood preasure (BP), glomerular filtration rate (GFR), cholesterol and peak 
expiratory flow rate (PEFR). 
 
3. Medication  
Relevant Medical History, Relevant Past Medication and Current medication 
are to be recorded in this section. 
 
4. Disease specific monitoring data  
CP-LTC focuses on monitoring of relevant patient data for cardiovascular 
disease (CVD), diabetes and pulmonary diseases. Therefore CVD Risk, lipid 
profile, HbA1c and MRC dyspnoea score are to be recorded in this section. 
 
5. Standard checks  
The standard check section can be described as a list of possible 
pharmaceutical care issues that need to be ruled out in each patient. If an 
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actual care issue is identified a check box is ticked. The standard checks in 
CP-LTC are sub divided into CVD prevention, hypertension, diabetes and lung 
disease. 
 
6. Monitoring notes 
Monitoring notes consist of a blank box for additional notes the PSP might 
want to take and a data fields to fill in the next 12-months review date. 
 
7. Standard treatment verifications 
In this section the PSP needs to verify weather the choice of medication and 
dose and the clinical/laboratory monitoring meet the guideline 
recommendations. Also there are check boxes for the identification of unmet 
preventive medication needs (CVD risk and osteoporosis) and the 
assessment of patient comprehension and ability to administer medication. 
 
8. Individualised care issues 
In the final section of the pharmaceutical care plan all identified care issues 
are to be summarised. Actions to be taken such as treatment plan changes, 
patient education or additional checks and an output need to be defined. 
 
 
4.2. Transformation of identified care issues into fields of data 
 
All pharmaceutical care issues, identified during literature research have been 
transformed into fields of data suitable for implementation into a 
pharmaceutical care plan by rephrasing, categorising and sorting by section, 
as shown in Table 5. A medication algorithm for pharmacotherapy of COPD 
(therapy scheme) has been generated from NICE guidelines, although it, 
among others, had to be revised completely, after new NICE guidelines were 
issued in June 2010.  
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Table 5: Transformation of identified care issues for patients with COPD 
into fields of data for implementation into CP-COPD-1 
Pharmaceutical care issue identified during 
literature research 
 
Implementation into a pharmaceutical care plan (CP-
COPD-1) 
 
Personal data 
Record smoking status 
Smoker, Cannabis smoker, Past smoker, Never 
smoked, Under cessation, Motivated to quit 
Record number of previous smoking quit attempts  Previous quit attempts:  
Calculate pack years Pack years:  
Record patient’s sex Male  Female 
Record weight, height and BMI Weight:, Unintentional weight loss, Height:, BMI: 
Record previous attendance in pulmonary 
rehabilitation or any other secondary care 
services 
 Seen by secondary care respiratory services:            
Record if patient had lung surgery  Attended surgery 
Find out about patient knowledge about COPD 
and educate if necessary 
Knowledge of COPD?    yes   no 
Record patient’s social circumstances (patient: 
Lives alone, is housebound, has professional 
carer, is in family care) 
Was already covered by CP-LTC: 
Social Circumstances: Lives alone  Housebound 
Professional carer Family care 
Patients who are not coping at home should be 
referred for home care support 
Specialist advice: social service 
Record if patient is on disease self-management 
plan 
Already covered by CP-LTC:   
 On disease self management plan  
Monitoring data  
Record pneumonia and influenza vaccination 
status 
Vaccinations (up to date?): 
Pneumonia   Influenza 
Monitor blood glucose level  HbA1C: 
Monitor plasma-electrolyte concentrations Urea and Electrolytes   normal  impaired: 
Record Blood Pressure (BP) 
Blood Pressure: four columns, each consisting of date and 
mm Hg 
Measure BP 
Blood Pressure: four columns, each consisting of date and 
mm Hg 
Record blood lipids 
Was already covered by CP-LTC: 
TC≥4mmol/L  HDL<1mmol/L  LDL≥2mmol/L      
and 
Cholesterol: four columns, each consisting of date and a 
blank box to fill in the Cholesterol value in mmol/L 
Disease specific monitoring data 
Assess MRC grade MRC GRADE 1  2  3  4  5 
Record spirometry results 
Spirometry: Three columns, each consisting of date, 
FEV1/FVC and FEV1 
Classify severity by spirometry results according 
to NICE 
*COPD profile Mild  Moderate  Severe 
Record reversibility testing results 
Reversibility with Salbutamol   no   yes     [more than 
15% response in FEV1 suggests  asthma] 
Record chest X-ray results Chest X-Ray: 
Record CT scan CT-scan: 
Record DXA scans DXA scan (DADS): 
Record number of exacerbations requiring 
antibiotics or oral corticosteroids in past year 
Number of exacerbations requiring Antibiotics and /or oral 
corticosteroids in past year:   
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Check if NICE therapy schema applies, and if it 
doesn’t record reasons for exclusion of certain 
drugs  
*Current COPD therapy: 
 SABA 
 +Tiotropium 
 +LABA 
 +Inhaled Steroid              
 
 +LTOT 
 Oral Steroid                                
  Theophylline                              
 Mucolytic (carbocistein) 
 Other: 
 
Medication 
Record co-morbidities 
Covered by ‘Relevant Medical History’, moreover an extra 
check box, coexisting asthma, was introduced 
Record if patient has a diagnosis of AAT-
deficiency 
Covered by ‘Relevant Medical History’ 
Standard checks 
Record if patient is pregnant Pregnancy 
Patients with a family history of AAT-deficiency or 
with young onset (aged <40 years) of COPD 
should be referred to a specialist 
Young onset or non-smoker: AAT-deficiency? 
If unexpected clinical worsening occurs, the 
patient should be referred to a specialist 
Unexpected change in symptoms or MRC grade: referral 
to  Spirometry Chest X-ray 
Use of theophylline should be verified and patient 
should be on therapeutic drug monitoring (TDM) 
Theophylline:  Use verified,  Plasmalevel monitored 
If respiratory diagnosis is unclear patient should 
be referred for clarification 
Respiratory diagnosis unclear: refer patient 
Offer entry to cessation program to smokers 
Was already covered by CP-LTC: 
Smoker offered entry to cessation programme 
Patients on ≥ 5mg/day prednisolone (or 
equivalent) for longer than three months should 
be referred to DADS 
Was already covered by CP-LTC: 
Oral steroid/6mths annual diabetes, BP & DADS 
Patients on high dose inhaled steroids (≥1000 
mcg beclometasone or equivalent) and have 
further risk factors for osteoporosis should be 
referred to DADS 
1000 mcg beclometasone + risk factors: DADS referral 
Patients older than 65 on oral Steroids should be 
on prophylactic osteoporosis  treatment, without 
monitoring 
>65 yrs  + oral steroids: Osteoporosis prophylaxis 
Assess if patients not on LTOT should be referred 
for LTOT assessment 
LTOT/ ambulatory OT assessment  required 
Patients with MRC≥3 should be referred for 
pulmonary rehabilitation 
MRC>2: referral to pulmonary rehabilitation 
Patients with abnormal BMI should be referred for 
dietetic advice/nutrition support; If BMI is low give 
nutritional supplements 
BMI<20: dietitian/ BMI>25: encourage  weight control 
Patients with clinical failure after all treatment 
options should be referred to a specialist to 
assess the need for palliative care 
On maximum doses +OT: if dyspnoeic: palliative care 
Assess if patient on self-management plan 
requires support or revision 
Exacerbations & self management issues discussed 
Patients with presence of peripheral oedema 
(ankle swelling) should be on diuretics 
Ankle swelling: cor pulmonale? 
Ask patient about dust or fume exposure Asked about occupational dust or fume exposure 
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Discuss management of anxiety and depression  Anxiety/Depression management 
Check if NICE therapy schema applies, and if it 
doesn’t record reasons for exclusion of certain 
drugs 
*>1 exacerbation/year + FEV1 < 50%: LABA + inhaled 
Steroid (not > 2x daily) 
Standard treatment verifications 
If patient’s symptom control is inadequate, more 
medication should be added 
Already covered by CP-LTC, Standard treatment 
verifications - care issue 1:  
 
Choice of medication/dose 
 
Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
verify choice of delivery system 
Standard treatment verifications - care issue 1: Choice of 
inhaler type 
 
Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
Assess if nebuliser therapy or spacer is applicable 
Already covered by CP-LTC, Standard treatment 
verifications - care issue 4:  
Assess patient’s comprehension and ability to administer 
medication (SPACER?) 
 
Inhaler Technique: 
            Poor   0    1      2      3  Satisfactory 
Assess patient’s inhaler and/or nebuliser 
technique  
Already covered by CP-LTC, Standard treatment 
verifications - care issue 4:  
Assess patient’s comprehension and ability to administer 
medication (SPACER?) 
 
Inhaler Technique: 
            Poor   0    1      2      3  Satisfactory 
Patients with chronic sputum production should 
be on carbocistein 
Already covered by CP-LTC, Standard treatment 
verifications - care issue 1: 
 Choice of medication/dose 
Check for unmet preventive medication (CV risk, 
osteoporosis, vaccinations) 
Already covered by CP-LTC, Standard treatment 
verifications - care issue 3:  
 
Check for unmet preventive medication needs: CV Risk     
Osteoporosis  
 
Candidate for   statin  aspirin  ACEI    ß Blocker  
Oral Biphosphonate  Ca & Vit D 
COPD patients on β-blocker should be under 
specialist supervision 
Already covered by CP-LTC, Standard treatment 
verifications - care issue 1:  
Choice of medication/dose,  Identified special precaution 
Patients with CVD, hypertension or arrhythmias 
who receive β-agonists should be under specialist 
supervision 
Already covered by CP-LTC, care issue 1:   
Choice of medication/dose 
 
 Identified special precaution 
Patients on warfarin need special precaution 
Already covered by CP-LTC: 
 
- Standard treatment verifications - care issue 1:  
  Choice of medication/dose   Identified special precaution 
- and ‘High risk medication user:   Warfarin’ 
 
*as according to NICE guidelines 2004; Has been subject of revision due to 
changes in NICE guidelines (see Table 10). 
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4.3. CP-COPD-1 
 
The starting point for designing a care plan for patients with COPD was CP-
LTC. To develop CP-COPD-1 mainly the sections ‘personal data’, ‘disease 
specific monitoring data - pulmonary function’ and ‘standard checks - lung 
disease’ of CP-LTC were expanded by the fields of data described in Table 5, 
while other sections such as ‘disease specific monitoring data - diabetes 
profile’ and some of the standard checks were replaced. All added data fields 
were included into CP-LTC with green font colour. The medication section 
was modified and moved from page one to page two due to shortage of 
space. The ‘Relevant Medical History’ and its ‘Past Medication’ subsection 
was expanded with the fields ‘Past medication trials without clear benefit’, 
‘Excluded medication’ and ‘Reason for Exclusion’.  
 
In the ‘Current Medication’ subsection one column to note the actual dose the 
patient takes, one column for comments on compliance, efficacy, adverse 
drug reactions (ADRs), critical incidences (CIs) and cost effectiveness and 
one column containing a check box to tick weather the drug showed clear 
benefit after one month or not was added next to each medication. At the 
bottom a field for recording of concordance issues and a box for the number 
of medications on repeat were inserted. The space for individualised care 
issues was reduced from 16 fields to ten, so that the third page of the care 
plan consists of ‘Individual care issues’ only and the care plan contains no 
more than three pages; If required the third page can be printed more than 
once. A complete list of removed fields of data and reasons for removing can 
be found in Table 6. In Table 7 all added fields of data and their sources are 
listed. 
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Table 6: Fields removed from CP-LTC to develop CP-COPD-1 
 
Field Comment 
Medication (section was moved from page one to page two) 
Disease Specific Monitoring Data 
     Past MI dates Recording of previous MIs is covered by the section ‘Relevant Medical History’ 
     Diabetes complications Recording of Diabetes and its Complications is covered by the section Relevant Medical History  
     COPD prognosis index, Mortality, Hospitalisations Do not influence the management of COPD 
     Obesity Profile – Target weight BMI, weight and height alone are sufficient to decide about dietetic advice and nutritional support 
     Combined medication scheme for COPD and asthma Was replaced with a medication scheme for COPD alone 
Standard Checks (all standard checks except in the section ‘lung disease’ were maintained) 
     Lung disease The headline ‘lung disease’ was replaced with ‘COPD’ 
     Suitability of multiple inhaler prescribing; on>2  
     inhalers has response confirmed 
Does not reflect the guideline recommendation, was replaced by the check box ‘clear benefit after 1 month’ in the 
‘Current Medication’ section 
     On inhaled steroid not > twice daily Care issue is already covered by the section ‘Standard treatment verifications’ – Choice of medication/dose 
     Oral steroid/6mths annual diabetes, BP & FRAX Was replaced with ‘Oral steroid/6mths annual diabetes, BP & DADS’, as FRAX is assessed as part of 
osteoporosis scanning by DADS 
     FRAX assessment (if>800 mcg/day) Was replaced with ‘1000 mcg beclomethasone + risk factors DADS referral’ (according to latest guideline 
recommendation) 
     COPD/asthma candidate for LABA Care issue is already covered by the medication scheme for COPD 
     Oral steroid/6mths is also on inhaled high dose Care issue is already covered by the section ‘Current Medication’ and the medication scheme for COPD 
Individualised care issues (number of fields was reduced from 16 to 10)  
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Table 7: Fields added to CP-LTC to develop CP-COPD-1 
Source 
Field 
Identified 
during 
literature 
research 
Contained 
in 
F-RR 
Suggested 
by 
Pharmacist 
Personal data 
     Tel No.    
     Age    
     GP    
     Specialist advice: social service    
     Knowledge of COPD    
     Attended surgery    
     Seen by secondary care respiratory services    
     Smoking status: Motivated to quit     
     Smoking status: Previous quit attempts    
     Smoking status: Cannabis smoker    
     Smoking status: Never smoked    
Monitoring data 
     Urea and electrolytes    
Disease specific monitoring data 
     Spirometry performed in practice or outreach    
     Spirometry record FEV1/FVC, FEV1    
     Chest X-Ray    
     MRC grade assessed by pharmacist, patient    
     Number of exacerbations requiring antibiotics and /or oral  
     corticosteroids in past year 
   
     Reversibility with Salbutamol    
     Coexisting asthma    
     COPD therapy algorithm    
Standard Checks 
     Pregnancy    
     Anxiety/Depression    
     BMI<20: dietitian/ BMI>25: encourage weight control    
     Asked about occupational dust or fume exposure    
     Young onset or non-smoker: AAT-deficiency?    
     Exacerbations & self management issues discussed    
     >1 exacerbation/year + FEV1 < 50%: LABA+inhaled Steroid     
     Theophylline: use verified, plasmalevel monitored    
     >65 yrs  + oral steroids: Osteoporosis prophylaxis    
     1000mcg beclometasone+risk factors:DADS referral    
     Encourage physical activity, exercise referral    
     Unexpected change in symptoms or MRC grade:   
     referral to  spirometry   Chest X-ray 
   
     LTOT/ ambulatory OT assessment  required    
     Ankle swelling: cor pulmonale?    
     MRC>2: referral to pulmonary rehabilitation    
     On maximum doses+OT: if dyspnoeic: palliative care     
Medication 
     Past medication trials without clear benefit    
     Excluded medication    
     Reason for exclusion of medication    
     Number of medications on repeat, [• medication on repeat]    
     Actual dose    
     Concordance issues    
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     Clear benefit (after 1 month)    
     Compliance, efficacy, ADRs, CIs, cost effectiveness    
Standard treatment verification 
     Choice of inhaler type     
     Necessity for spacer    
Monitoring notes 
     Date of review    
     Ie Read code:  Asthma, COPD, Other    
     Exception coded from COPD review    
     House visit, phone review    
     Follow up, phone review required    
     Time taken for review    
     Costs saved or incurred    
 
 
4.4. CP-COPD-2 
 
CP-COPD-1 was improved in form and content. More pharmaceutical care 
issues could be identified and also new NICE guidelines for COPD have been 
issued after CP-COPD-1 had been field tested and while CP-COPD-2 was 
developed in June 2010.  
 
4.4.1. Structural improvements 
 
During the first field testing it was found that a more structured and simplified 
design might be useful. This was obtained by different moves: 
 
4.4.1.1. Division of data fields into two groups 
 
Data field were divided into (1) data that can be filled out before the patient is 
seen, and (2) data which have to be assessed with the patient during a face to 
face dialogue or afterwards the meeting. This is reflected by white (1) and 
grey (2) shading of the data field. Therefore the fields social circumstances, 
smoking status, latest BP, latest MRC grade, latest HADS scores, most of the 
monitoring notes, and several standard checks were shaded grey.  
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4.4.1.2. Sorting of data fields 
 
Another approach to obtain a more structured plan was to sort data fields, 
both spatially and with regard to contents. A new section ‘COPD profile’ was 
introduced. The section ‘disease specific monitoring data’ was abrogated and 
its data fields were embedded either into the ‘monitoring data’ or into the 
‘COPD profile’ section. All monitoring data were arranged next to each other 
on the left side of page one. The ‘COPD profile’ section, located in the middle 
part of page one, contains NICE classification of severity, BODE index, 
patient’s age at initial diagnosis, numbers of exacerbations, LTOT assessment 
parameters, a list of co-morbidities and the NICE therapy schema. A list of the 
most prevalent co-morbidities was included. Multiple checks for one care 
issue were reduced and some fields were identified as unnecessary and 
removed.  
 
4.4.1.3. Revision of ‘standard checks’ 
 
The subdivisions were removed and the standard checks were sorted by 
incidence and priority rather than by disease. A consistent format was 
introduced by rephrasing the standard checks: The possible care issue was 
formatted in bold font, and the consequent action in normal font, like for 
example: ‘Hypertensive patient on treatment’. The pharmacist checks 
whether any of the possible care issues (bold font) apply to the patient, and if 
so, they check if the consequent action (normal font) has been taken. In case 
it has not, an actual care issue has been identified, which is indicated by 
ticking the associated check box ‘care issue’. A second check box, ‘action’, 
next to each standard check has been introduced in CP-COPD-2. It is ticked 
to signalise that the consequent action has been taken, in case of the 
previous example, the action is to put the hypertensive patient on treatment.  
 
A complete list of structural improvements can be found in Table 8. 
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Table 8: Structural improvements in CP-COPD-1 to develop CP-COPD-2 
 
Field Comment 
Personal data 
     Specialist Advice (Diet, Exercise, Smoking, social  
     service) 
Removed, as covered by the standard checks: , ‘BMI abnormal nutritional supplements, refer to dietician’, 
‘Smoker offered entry to cessation programme’ and ‘Not coping at home refer for home care support’ 
     Attended pulmonary rehabilitation Added. Was previously covered by ‘seen by secondary care respiratory services’, but was found to be more 
convenient as a separate option 
     No. Cigs./day This additional field allows a quick overview over the patient’s smoking habits, while the calculation of pack years is 
more time consuming 
      Dust/fumes exposure Added, replaces standard check ‘Asked about occupational dust or fume exposure’ 
      Cannabis smoker Removed, as during field testing none of the patients admitted to be cannabis smoker. 
      Desire to quit Added, replaces ‘ Motivated to quit’  
Monitoring Data 
     Unintentional weight loss Removed as covered by standard check: ‘BMI abnormal nutritional supplements, refer to dietician’ 
     Glucose (<6, 6-7, >7) Added. Replaces the field ‘HbA1c’ 
     Diabetes risk  Removed, as calculation is time consuming and not supported by GPASS and result does not influence therapy 
     Fracture risk Removed, as calculation is time consuming and not supported by GPASS, already covered by ‘DXA scan’ 
     CVD risk Replaced with CVD risk (assign)  
Assign is the cardiovascular risk score chosen for use by Scottish Intercollegiate Guidelines Network (SIGN) and 
Scottish Government Health Directorates [72] and is supported by GPASS 
     Reversibility with Salbutamol  
     (yes, no) 
Check boxes (yes, no) were replaced with blank boxes for percentage of reversibility, attached to each spirometry 
result 
     PEFR Removed as not state of the art of science 
     Cholesterol Row with four columns for last four records of cholesterol was replaced by one check box ‘ Chol ≥ 6’ next to lipids 
     MRC grade More columns were added to record latest three MRC assessments 
COPD profile 
     Knowledge of COPD? (yes, no) Replaced with standard check ‘Patient knowledge inadequate provide education’ 
     Coexisting asthma Included into the section with a list of co-morbidities 
     Comorbidities (AAT-Deficiency, Asthma, Cor  
     pulmonale, CVD, Depression, Diabetes, Glaucoma,  
     Hypertension, Osteoporosis, Other) 
Added to give an overview over the most prevalent co-morbidities, as this is essential information for choosing 
treatment. 
     Patient’s age at initial COPD diagnosis Added, as this gives information about possible early onset and duration of disease 
Standard Checks 
     Pregnancy Rephrased: Pregnancy confirmed refer to specialist 
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     BMI<20: dietitian/ BMI>25: encourage  weight control Rephrased: BMI abnormal nutritional supplements, refer to dietician 
     CHD – ‘0n aspirin achieved a BP ≤ 150/90mm/Hg’ Removed, as already covered by  ‘Hypertensive patient on treatment’ 
     Aspirin C/I, on Clopidogrel 75mg Removed, as already covered by Standard treatment verifications - care issue 3:  
Check for unmet preventive medication needs: CV Risk  
     Stroke or TIA history on dipyridamole 200mg BD Removed, as already covered by Standard treatment verifications - care issue 3:  
Check for unmet preventive medication needs: CV Risk  
     TC≥4mmol/L on Statin unless  C/I Removed as already covered by Standard treatment verifications - care issue 3:  
Check for unmet preventive medication needs: CV Risk , Candidate for   statin 
     Not prescribed combination of thiazide & b/blocker Removed as already covered by Standard treatment verifications - care issue 1: 
Choice of medication - Meets guideline recommendations  Identified exception Identified special precaution 
     Diabetes/CVD /Chronic Renal Failure  
     blood pressure optimised (≤130/≤80) 
Rephrased: Diabetes/CVD /Chronic Renal Failure BP ≤130/≤80 
     Diabetes – ‘AII antagonist   indicated /    use  
     verified’ 
Removed as already covered by Standard treatment verifications - care issue 1: 
Choice of medication - Meets guideline recommendations  Identified exception Identified special precaution 
     Diabetes – ‘BMI> 26(F)/27(M) kg/m
2
 on metformin’ Rephrased: Diabetes + BMI> 26(F)/27(M) kg/m
2
 on metformin 
     + BP Controlled, CVD≥20% on aspirin 75mg Removed as covered by: Standard check ‘10yr CVD risk ≥20% , Age>40 on aspirin 75mg’ 
     Asked about occupational dust or fume exposure Removed, replaced with check box in personal data:  Dust/fumes exposure 
     Young onset or non-smoker: AAT-deficiency? Rephrased: COPD onset<40yr, FH AAT-Deficiency refer to specialist 
     Exacerbations & self management issues     
     discussed 
Rephrased: On self management but requires revision/support 
     Theophylline:  use verified,  plasmalevel  
     monitored 
Rephrased: On theophylline use verified,  on TDM 
     Oral steroid/6mths annual diabetes, BP & DADS Rephrased: ≥5mg prednisolone/3mths annual diabetes, BP + DADS 
     >65 yrs  + oral steroids: Osteoporosis prophylaxis Rephrased: >65 yrs  + oral steroids osteoporosis prophylaxis 
     1000 mcg beclometasone + risk factors: DADS    
     referral 
Rephrased: ≥1000 mcg beclometasone+ risk factors refer to DADS 
     Respiratory diagnosis unclear: refer patient Rephrased: Respiratory diagnosis unclear refer  for clarification 
     Unexpected change in symptoms or MRC grade:    
     referral to  spirometry   Chest X-ray 
Rephrased: Unexpected clinical worsening refer to specialist 
     LTOT/ ambulatory OT assessment  required Rephrased: On maximum medication refer for LTOT assessment 
     Ankle swelling: cor pulmonale? Rephrased: Oedema presence (ankle swelling) on diuretics 
     MRC>2: referral to pulmonary rehabilitation Rephrased: MRC≥3 refer to pulmonary rehabilitation 
     On maximum doses +OT: if dyspnoeic: palliative    
     care  
Rephrased: Clinical failure after all treatment options refer to specialist (palliative care) 
     Patient knowledge inadequate provide education Added, replaces COPD profile: ‘Knowledge of COPD yes, no’ 
     Symptom control inadequate adding of medication Added, was previously covered by COPD Profile – medication schema, but found to be useful as an additional 
standard check 
     Not coping at  home  refer for home care support Added, replaces Specialist Advice (Diet, Exercise, Smoking, social service) 
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     Chronic sputum production  on carbocisteine Added, was previously covered by COPD Profile – medication schema, but found to be useful as an additional 
standard check 
     Warfarin + severe COPD decrease dose by 33% Added, was previously covered by Standard treatment verifications - care issue 1: Choice of medication/dose   
Identified special precaution and ‘High risk medication user:   Warfarin’ but found to be useful as an additional 
standard check 
Medication (more rows for medical history and current medicines were added) 
     Current medication – ‘compliance, efficacy, ADRs,  
     CIs, cost effectiveness’ 
Replaced by ‘column Comment’ 
     Current medication – ‘Concordance issues’ Removed, as now covered by ‘comment’ 
     Relevant Medical History/ Relevant Past Medication  
     Excluded medications – ‘Trial: from – to’ 
Added, as a field for date was lacking 
Standard treatment verifications 
     Choice of inhaler type Replaced by ‘choice of delivery system’, as the term delivery system is more general 
     Check for unmet preventive medication needs    
     Vaccinations       
Added, was previously covered by ‘COPD-Profile Vaccinations’ 
     Nebuliser use verified Added, was previously covered by ‘Choice of inhaler type’, but found to be useful as an additional check box 
     Candidate for  Spacer    Nebuliser Added, replaces ‘SPACER?’ 
Monitoring notes 
     Exception coded from COPD review Removed as identified as irrelevant 
     Review: clinic The data field with the options ‘House visit’ and ‘Phone review’ was changed to ‘Review: House visit, Phone, Clinic’ 
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4.4.2. Editing of content 
 
4.4.2.1. New care issues and data fields 
 
Eight new pharmaceutical care issues in patients with COPD regarding 
depression and anxiety management, LTOT and medication precaution were 
identified during field testing of CP-COPD-1. After performing a literature 
review on them, they were included into the introduction of this report. Then 
they were transformed into fields of data for inclusion in a care plan and 
implemented as shown in Table 9. 
 
Table 9: Transformation of identified care issues for patients with COPD 
into fields of data for implementation into CP-COPD-2 
 
Monitoring data 
Record previous HADS scores HADS-D & HADS-A: date: 
Assess HADS score  HADS-D & HADS-A: date: 
COPD profile 
Record LTOT assessments (including 
PaO2 and SaO2) 
 LTOT assessment     date: 
PaO2:, SaO2: 
Standard checks 
Discuss possible adverse effects from 
steroids with the patient 
On steroids educate about adverse effects 
Assess if LTOT is used a sufficient 
amount of hours (>15) per day 
Patient on LTOT on >15 hours/day 
COPD patients on β-blocker should 
be under specialist supervision 
Beta blocker + COPD under specialist 
supervision 
Patients with CVD, hypertension or 
arrhythmias who receive β-agonists 
should be under specialist 
supervision  
CVD/↑BP/arrhythmia + β-agonist 
specialist supervision 
Discuss management of anxiety and 
depression in patients with HADS-D 
or HADS-A ≥8 
HADS-D or HADS-A≥8 Anxiety/Depression 
management 
(replaces standard check  
‘Anxiety/Depression management’) 
 
 
4.4.2.2. Implementation of changes in NICE guidelines 
 
New NICE guidelines for COPD have been issued between CP-COPD-1 and 
CP-COPD-2 in June 2010 and the introduction of this report was revised. 
Changes in guidelines include a new classification of severity, introduction of 
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a very specific medication algorithm, and assessment of BODE index.  A clear 
benefit from pharmacologic treatment after a one month trial is no longer 
required. All changes to CP-COPD-1 due to the new issue of the NICE 
guidelines are summarised in Table 10.  
 
Table 10: Changes from CP-COPD-1 to develop CP-COPD-2 due to new 
NICE guidelines 
 
CP-COPD-1 CP-COPD-2 
COPD Profile 
     NICE classification of severity: 
     Mild  Moderate  Severe 
Replaced by: 
NICE: 
 Mild   [FEV1 ≥80%]   Severe [30-49%] 
 Moderate [50-79%]    Very Severe 
     [<30  or  <50 + RF] 
     
     Medication scheme: 
 
Current COPD therapy: 
 SABA 
 +Tiotropium 
 +LABA 
 +Inhaled Steroid              
 
 +LTOT 
 Oral Steroid                                
  Theophylline                              
 Mucolytic (carbocistein) 
 other: 
   
Replaced by: 
 
Medication: 
 
 SABA or  SAMA 
 
 FEV1 ≥ 50%  FEV1 < 50% 
LABA  LAMA   
{LABA+IC}
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA 
{LABA+IC}
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA + 
   {LABA+IC} 
LAMA + 
   
{LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   
{LABA+IC} 
 Oral Steroid           Mucolytic (carbocistein) 
 Theophylline         Other: 
   
     Calculate BODE index Added 
Standard checks 
     >1 exacerbation/year + FEV1 < 50%:    
     LABA+inhaled Steroid (not > 2x daily) 
Removed 
     On  SAMA+LAMA switch to SABA 
Added 
Medication 
     clear benefit after 1 month Removed 
     Relevant Medical History/ Relevant Past    
     Medication – Past medication trials   
     without clear benefit 
Removed 
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4.5. CP-COPD-3 
 
4.5.1. Division of pages  
The main improvement of CP-COPD-2 was to split the pages of the care plan 
into one page for ‘recording data’ (data that can be obtained from the patient 
file e.g GPASS) and four ‘review’ sheets.  
 
4.5.1.1. ‘Recording data’ sheet (page one) 
The section ‘Standard checks’ and all fields for data that need to be assessed 
by the pharmacists were moved from page one to other pages and so page 
one now is for recording of data only: The fields patient data, monitoring data 
and COPD related recording data (Co-morbidities, Vaccination, LTOT 
assessment, BODE index, ‘Patient’s age at initial COPD diagnosis’ and ‘No. of 
exacerbations’) were maintained on page one and a row to fill in the date was 
attached to them.The previous introduced concept of shading data fields that 
have to be assessed with the patient during the face-to-face dialogue grey, 
was not considered as applicable on the ‘recording data sheet’ and was 
therefore disintegrated on the ‘recording data sheet’.  
  
4.5.1.2. ‘Review’ sheets (pages two - five) 
All fields for the actual medication review were placed on the pages two to 
five. The second page is now entirely occupied by the ‘medication’ section. 
The field ‘High risk medication’, formerly part of personal data, is now included 
in the ‘medication’ section and located on bottom of page two. Page three now 
consists of: monitoring notes; standard treatment verifications; assessment of 
risk factors (including smoking status), and the COPD medication scheme. 
The section ‘standard checks’ is now placed on page four and page five 
contains the table for individualised care issues.  
 
 
 
 - 56 - 
4.5.2. Creating more space 
The number of pages was expanded from three to five. This made a scaling 
up of the font size from eight to twelve possible, and enabled the creating of 
more space for multiple records of data on page one (for example the number 
of columns for BP and Spirometry values were expanded from three to five).  
 
A summary of feedback by the pharmacists and the description of its 
implementation are listed in Table 11. 
 
Table 11: Summary of feedback by pharmacists and description of 
implementation 
Feedback by pharmacists Description of implementation 
The font on the first page is too small to be easily workable. 
The font size was scaled up from 8 to 12 after more 
space was obtained by moving sections and 
expanding the care plan from three to five pages. 
Personal data 
Two separate boxes to record CHI and DOB are needed A seperate box for CHI was introduced. 
The Ref number at thetop, what’s that for? Ref. number was removed 
I am not convinced that surgery is necessary to have on. ‘Attended surgery’ was removed 
The fields about self management should be changed to 
look something like: 
 
COPD self management plan         YES/NO 
Attended Pulmonary Rehabilitation YES/NO 
(If yes, when?) 
Appropriate for referral to Pulm RehabYES/NO 
Other secondary care services YES/NO 
(If yes, details) 
 
Maybe dates would be useful here instead of a tickbox? 
The fields were changed to: 
 
On COPD self management plan  no yes–date:       
Attended pulmonary rehabilitation  no yes-date:       
Other secondary care services:                        date: 
 
The suggestion ‘Appropriate for referral to Pulm 
Rehab YES/NO’ was not realized at this location as 
this section is for recording of patient data only and 
moreover the care issue is already covered by 
standard check ‘MRC≥3 refer to pulmonary 
rehabilitation’. 
The box about self management plans should be moved to 
after the recording of MRC grade 
The box was not moved, as moving to after the 
recording of MRC grade would only make sense if the 
field ‘Appropriate for referral to Pulmonary 
Rehabilitation YES/NO’ had been implemented at this 
location. 
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Smoking: 
The third box I would change to: 
 
     Pack Years: 
     Currently using NRT  
     Ready to quit  
     Unwilling to quit  
     No of quit attempts: 
     Products used in failed attempts: 
The Assessment of smoking status was redesigned 
and moved from page one to page three and 
implemented into the section ‘Pharmaceutical care 
review – Assessment of risk factors’: 
 
Assessment of risk factors: 
Smoker Past Smoker  Never smoked 
Under 
cessation 
Occupational dust/fumes 
exposure: 
 
Pack years  
No. 
Cigs./day 
 
Currently using 
NRT 
no     yes: 
 
 
Ready to quit Unwilling to quit 
 
Previous quit attempts  
Products used in failed 
attempts 
 
    
Monitoring data 
GFR, Glucose, Lipids:  I would just leave the boxes blank for 
the pharmacist to write the level in themselves. 
check boxes for values were replaced with: 
‘ normal        impaired:                 ‘ 
Liver function tests (LFTs) need to be included in the 
investigations part. 
‘LFTs date:        normal     impaired:        ’ 
was included 
COPD Profile 
The severity scale needs to go immediately underneath the 
spirometry details. 
The NICE severity scale was moved underneath the 
spirometry details 
There needs to be much more space to enter details of co-
morbidities and I think this needs to go further up the page 
as this is an essential piece of information to get. 
 
Also under "co-morbidities" can there be a box for "none"  
The Co-morbidities section was expanded significantly 
and moved into an own section on the ‘Recording 
data sheet’. 
 
 
A check box for ‘none’ was included 
 
 
Allergies were removed from the personal data 
section and included into the Co-morbidities. 
Standard checks 
The Standard Checks might not be necessary to have. My 
recommendation would be to have a ‘reminder page’ at the 
back containing this information that people can use if they 
want or else just not print it off.  This list would help 
pharmacists very new to running clinics. 
Standard checks were moved to a seperate sheet on 
page four. 
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The line ‘On SAMA+LAMA switch to SABA’ is not correct. 
The pharmaceutical care issue  
• Patients on  SAMA and LAMA should be 
switch to SABA  
had been identified incorrect. The correct care issue 
is: 
• Patients on regular SAMA ≥ 4/d should be 
switched to LAMA  
 
The data field  
‘On SAMA+LAMA switch to SABA’  
was replaced by   
‘On regular SAMA ≥ 4/d switch to LAMA’ 
Medication 
High risk medications:  I think that if you are going to include 
this box it should be on the second page. 
Can the "high risk medication user" be changed to "High risk 
Medications" and add a box for "none" as an empty box 
could sometimes be an oversight so adding a "none" rules 
that out. 
‘High risk medication user’ was renamed to ‘High risk 
medication’, and placed in the section ‘Medication’ on 
the second page. A check box for ‘none’ was 
included. 
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5. DISCUSSION 
5.1. Developing a pharmaceutical care plan 
The aim of this research was to develop a pharmaceutical care plan 
specifically for patients with COPD. The resulting work (CP-COPD-3) should 
be understood as one of many parts of a comprehensive care plan which will 
be developed to be used in every patient with any chronic disease, rather than 
as a self-contained project. 
 
Pharmaceutical care issues for patients with COPD have been identified via a 
comprehensive literature review. To ensure consideration of all relevant 
topics, the content of this literature review was carefully compared with the 
latest guidelines. Following this phase, a pharmaceutical care plan for patients 
with COPD was developed in the following stages: 1) Starting with an existing 
pharmaceutical care plan, several fields were removed and replaced with 
fields identified as important for patients with COPD. 2) This first design was 
then field tested and identified improvements were implemented. 3) This 
process was then repeated until no further improvements were found. 4) The 
design was then field tested by experienced pharmacists running medication 
review clinics. 5) Their professional feedback was then incorporated into the 
final version of the care plan. 
 
5.1.1. Selecting of care issues and level of detail 
The problem of identifying care issues and implementing them (as data-fields) 
into the care plan at a sufficient level of detail was a particularly difficult task. 
Some of the identified care issues were found to be too detailed and some too 
broad, while others might not have been identified at all. While generally 
recognized care needs were covered by general wording such as the 
standard treatment verifications “Choice of medicine/dose/delivery system” 
and ‘Check for unmet preventive medication needs’, more specific care issues 
were implemented as detailed standard checks like ‘Patient on LTOT on >15 
hours/day’ or ‘≥5mg prednisolone/3mths annual diabetes, BP + DADS’. 
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However, the identification, selection and prioritisation of care issues into a 
care plan remains an individualised and subjective process within the context 
of intuitive clinical work; thus extensive field-testing on a larger sample of 
patients is essential to ensure that care issues are incorporated into the plan 
at the correct level of detail. 
 
A particularly important point in this regard is that some standard checks are 
very specific and might only apply in a minority of patients, while a very broad 
formulation runs the risk of pharmacists forgetting to check for important 
issues. For example the very broad, generally recognized, care issue, ‘The 
patient needs to receive the right medicines’ can be formulated in the very 
general phrase: ‘Choice of medicine/dose/delivery system  Meets guideline 
recommendations,  Identified exception,  Identified special precaution’ or it 
can be broken down into several very detailed standard checks: 
‘Hypertensive patient on treatment’, ‘On regular SAMA ≥ 4/d switch to 
LAMA’, ‘Patient with CVD prescribed aspirin & statin’ and many more. And 
even most of the already very detailed standard check such as ‘Hypertensive 
patient on treatment’ can be in-depth more: ‘↑BP, ≤ 55yr, non-black on ACE 
inhibitor’, ‘↑BP, >55yr, black on thiazide diuretics/ Ca Blocker’ and so on. 
 
In this care plan both general treatment verifications and detailed standard 
checks were implemented. One of the pharmacists who field-tested the design 
gave the following feedback about the detailed standard checks: “I am 
undecided about whether the Standard Checks are necessary to have. My 
recommendation would be that you have a ‘reminder page’ at the back 
containing this information that people can use if they want or else just not 
print it off. This list would really only be necessary to pharmacists very new to 
running clinics so I do think a reminder sheet would be helpful for them.” 
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5.1.2. Structuring the care plan 
It has been found that a well-structured design is essential. This was obtained 
by different approaches: 
 
5.1.2.1. Division of data fields 
In the very early stages of developing the care plan it became clear that 
division of data fields into different categories is useful, and a categorial 
difference (reflected by different shading of the boxes) was made between 
those fields that can be filled out before the patient is seen and those that 
have to be assessed during a face-to-face dialogue with the patient. Later, the 
care plan was further sub-divided into fields that can be completed using data 
from the patient’s existing record and data that are the object of the actual 
medication review: 
 
The ‘Recording data sheet’ on page one of the care plan is for the recording 
of existing data obtained from the patient file before the patient is seen, such 
as personal data, monitoring data (lab results) and COPD-related data (for 
example, co-morbidities, vaccinations and LTOT assessment). Page one is 
independent of the ‘review’ section and in case of any further medication 
reviews, it can remain as the first page of a patient folder/computer record and 
need only be updated with the latest values.  
 
The ‘Review sheets’ (pages two - five) contain all fields of data for the actual 
medication review. These can be understood as work sheets for the 
pharmacist.  
 
5.1.2.2. Sorting of data fields 
To obtain a structured care plan, data fields were sorted to group similar fields 
spatially. For example all monitoring data were arranged next to each other on 
the left side of page one, all COPD related recording data on the right side of 
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page one and the entire medication section was placed on the second page. 
Multiple checks for one care issue were avoided, with the exceptions of: 
• A list of most prevalent co-morbidities was included on page one 
although this care issue was already covered in the ‘medication’ 
section. The summary on the first page allows an overview, as co-
morbidities are essential information for choosing the right treatment.  
• The additional field ‘high risk medication’ with check boxes for 
medications such as digoxin, high dose inhaled corticosteroids and 
warfarin represents a safety net to make sure risk medication is 
identified as such and considered when choosing or changing the 
treatment. 
 
5.1.2.3. Unambiguous labelling 
Exact and specific expressions were used to prevent misunderstandings 
about the kinds of data requested in each field. As dates are attached to all 
monitoring data values, it can easily be recognized if the latest assessment 
(for example of BP or MRC grade) is out of date, and the health care 
professional can carry out the assessment and fill-in the obtained value.  
 
A data field without any ticked check boxes might give the impression that it 
has not been filled out. To ensure that every data field is considered by the 
person who fills out the care plan, fields of data containing lists such as ‘high 
risk medications’ and ‘co-morbidities’ were amended with check boxes for 
‘none’. 
 
5.1.2.4. Font size 
A major criticism from the pharmacists was that the font size of eight point 
was too small in the earlier versions of the care plan (CP-COPD-1, CP-COPD-
2) was. Font size point twelve was found to be workable.  
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5.1.2.5. Automatic highlighting of impaired values by using check 
boxes 
 
In the earlier versions of the care plan (CP-COPD-1, CP-COPD-2) the 
recording of lab parameters such as glucose, GFR or blood lipids was via 
check boxes. The pharmacist simply indicates fixed values as for example: 
‘GFR [ml/min]:  >50,  50-30, <30’, while other data fields, such as BP 
and cholesterol, gave a blank space into which the pharmacist would write the 
exact value. Check boxes allow a quick overview, as it can be seen more 
easily if a value is impaired. The pharmacists preferred the second option, 
however: empty boxes to fill-in values. A compromise was arrived at in the 
final version of the care plan, where data fields give check boxes for ‘normal’ 
and ‘impaired,’ and a blank box next to it to write down the impaired value. 
 
5.1.3. Tools for designing 
The care plan was designed using an existing pharmaceutical care plan 
template in Microsoft Word, which was found to be cumbersome and led to 
frequent formatting issues. The use of more flexible design tools, or the 
introduction of an electronic system as suggested in section 5.5.2. below 
would allow the researcher to focus on the content, rather than the design, of 
the care plan in its formative stages.  
 
5.2. Pharmaceutical care provision in Scotland 
 
In 2009 the Scottish Government published a report about the establishment 
of therapeutic partnerships between community pharmacists, general medical 
practitioners (GP) and patients, on which the currently negotiated Chronic 
Medication Service (CMS) element of the Community Pharmacy Contract 
within NHS (National Health Service) Scotland is built. The CMS is a new 
approach to involving community pharmacists in the management of patients 
with long term conditions, such as COPD, and is based on the collaboration 
and communication between different healthcare professionals.  
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Patients with long term conditions within this new contract are envisaged to be 
able voluntarily to register for the CMS in their local community pharmacy. 
Once the patient has done so, the patient’s electronic record gets flagged as 
‘CMS registered’, which enables the GP to generate electronic serial 
prescriptions of medicines, and gives the pharmacist the opportunity to 
provide care to the patient [5].  
 
Currently, in advance of a formal role for community pharmacists, local 
schemes are using pharmacists to undertake medication reviews. In the 
community health centres visited during this research COPD Support 
Pharmacists and PSPs are performing full medication reviews for patients with 
COPD. As part of this process, an appointment for a face-to-face dialogue 
with the patient is arranged. In this setting, the patient’s GP has to approve 
the recommended changes in the treatment plan by the pharmacist. If the 
pharmacist is an independent prescriber (PSP) they can sign the new 
prescriptions, otherwise they are given to the GP to sign.  
 
5.2.1. Limitations of the current services 
• Within the current medication reviews provided to patients with 
COPD, the pharmacists who specialise in COPD may not give 
adequate attention to co-morbidities by limiting the focus to COPD 
alone.  
• By expanding the existing services to community pharmacies, a 
larger number of patients can benefit from systematic care provision. 
Through implementation of CMS a big step in the right direction will 
be achieved. 
• Finite resources need to be best distributed, and this requirement 
needs to be balanced with the ideal wish to most fully improve each 
patient’s quality of life by providing the best available treatment and 
a yearly medication review [6].  
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5.2.2. Limitation of the current clinical documentation 
Patients are targeted for a medication review in a community health centre by 
their read codes in GPASS. The GP’s system is also used to obtain patient’s 
records and to input a summarised report after the appointment. Obtaining 
patient data from GPASS is time-consuming and cumbersome, as much data 
does not exist in the form of data fields, but is buried within free text or 
scanned patient documents. 
Some of the pharmacists shadowed for this research are currently using the 
‘respiratory review form’ (F-RR) as a work sheet and for documentation of the 
services they provide. This form focuses on COPD and asthma only and does 
not contain the following data fields: 
 
• Complete list of current medication 
• Lab results such as blood lipids, cholesterol, glucose and GFR 
• Assessments such as BODE index, BP HAD scores and CVD risk  
• Checklist for unmet preventive medication needs (osteoporosis, 
cardiovascular risk) 
• Detailed medication scheme 
• Comprehensive and detailed standard checks 
• Comprehensive smoking status assessment form 
• List of co-morbidities, date of diagnosis and associated clinical data 
• Recording of medication history and excluded medication 
• Highlighting of high-risk medication 
 
5.3. Advantages of the new care plan 
The care plan for patients with COPD that has been developed is detailed, 
comprehensive and summarises all relevant data. If the documentation is 
filled out accurately and in full, it ensures consideration of all potential care 
issues covered by the care plan. Its design, especially that of the standard 
checks, the medication scheme and the assessment of the smoking status, 
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are intuitive and do not require lengthy instruction. The care plan allows 
efficient task sharing between different health care professionals. 
 
5.3.1. Task sharing 
The division of the care plan into a ‘recording sheet’ and ‘review sheets’ 
resulted in a page containing mainly lab results and previous diagnoses, 
which could be collected and filled out by a technician, followed by worksheets 
for the actual medication review which is carried out by a pharmacist. This is 
supported by Hudson et. al., who further argue that the initial documentation, 
patients’ education and administration of medicines (especially inhaler 
technique) might be carried out by a technician before referral to the 
pharmacist [3]. This suggests a possible time-saving measure, for while in the 
medication reviews run by the community health centres shadowed during this 
research, the entire assessment, including preparation work (for example 
obtaining relevant information from patient files) was carried out by a PSP. 
 
5.3.2. Other functions of clinical documentation: 
• Peer review sharing of experience and obtaining colleagues views 
and therefore a way of reviewing the service 
• Sharing information with other healthcare professionals 
• Enables discussion of individual cases with other colleagues  
• Medico-legal function 
• Evidence of service being provided and therefore evidence to 
support payment for the service 
• A way of training pre-registration pharmacists 
 
5.4. Limitations of the pharmaceutical care plan 
The limitations of a very detailed care plan, such as developed during this 
research, might be that pharmacists are tempted to stop using their skills and 
knowledge and trust only in the care plan. This could lead to pharmacists 
forgetting their knowledge and diminution of feelings of responsibility, as the 
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care plan might give the false impression of covering all possible 
circumstances and conditions. The use of a computer based system might 
further exacerbate these risks. Another problem might be that Pharmacists 
are focusing on the documentation more than talking to the patient. Both 
classroom education and practical implementation with experienced role 
models would be necessary to minimise the risk of making these mistakes. 
 
5.5. Future prospects 
5.5.1. Introduction of systematic care provision and documentation 
CMS is a promising approach for involving community pharmacists in 
systematic care provision for patients with chronic conditions such as COPD. 
Its introduction enables pharmacists to provide systematic care to a large 
number of patients by performing regular medication reviews. As suggested 
by the Scottish government, areas of inter-professional working, 
communications, and education and continuing professional development 
need to be improved to support the successful implementation of CMS [5], so 
that systematic care can be provided to patients not only in community health 
centres with pharmacists running medication review clinics, but in every 
community pharmacy. 
 
5.5.2. Electronic solution 
Anecdotal evidence suggests that some pharmacists favour the introduction of 
a computer application for care planning. The advantages of an electronic 
version of a care plan would be: 
• Design problems as discussed in section 5.1.3 above could be 
circumvented 
• Automatic identification of pharmaceutical care issues 
• Automatic recommendation of actions to be taken to resolve an 
identified care issue 
• It might be possible to integrate an electronic care plan application 
into the Patient Medication Record (PMR) system which is currently 
used in community pharmacies in the UK [5], and connect it with the 
GP’s IT systems 
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• In that case, necessary patient data like lab results or the patient’s 
current medication could be collected and summarised 
automatically, and then printed off. Similar interactions between the 
pharmacy’s and the GP’s IT systems are already in use, as for 
example in the patient registration process for CMS [5].  
• Automatic highlighting of instances where data is lacking 
• Simplification of audit procedures (for example that of adherence to 
guidelines) 
 
Current limitations to the realisation of an electronic care plan are: 
• As described in section 5.2.2 above, many of the GP’s patients’ 
results are not in the form of data fields and can therefore not be 
transferred easily into fields of data, as would be necessary for an 
electronic care plan.  
• The future implementation might reveal the collection of data which 
the pharmacists can collect but which are not routinely collected by 
the doctor. 
• There are obvious data protection issues: the electronic transfer of 
information is the subject of great concern about privacy and in 
certain countries the legal right to privacy may be a serious barrier.  
 
5.5.3. Guidelines 
The development of a pharmaceutical care plan such as has been the focus 
of this study would be eased by the creation of guidelines, which would 
provide care plan developers with a common structural framework and define 
categories of data for inclusion. Another potential approach would be the 
direct integration of a draft of a care plan into every guideline issued by clinical 
practice guideline developers such as NICE and SIGN. In developing 
recommendations for the care of patients, they undertake reviews of the best 
available evidence and are therefore highly qualified to identify and prioritise 
pharmaceutical care issues and develop pharmaceutical care plans. This is 
partially happening already: see, for example, the appendix of the latest 
COPD guidelines [6], which contains a detailed algorithm for inhaled 
therapies, generated from guideline recommendations.  
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5.5.4. Future research about COPD 
So far no cure for COPD has been found. Improvement of long acting inhaled 
bronchodilators, further investigation of the connection between vitamin D and 
respiratory health and the revision of corticosteroid resistance are promising 
approaches in COPD therapy and more research is going on. The impact of 
risk factors, gender and genetic factors needs to be researched further. 
Smoking cessation and prevention programmes need to be improved. The 
NICE guidelines [6] suggest the following other areas for future research into 
treatment of COPD: 
• Research the benefits of pulmonary rehabilitation during hospital 
admission 
• Finding a simple multidimensional assessment of outcomes, as the 
BODE index assessment is impractical 
• Research whether triple therapy improves outcomes compared to 
single or double therapy, including health economic evaluation. 
• Investigate whether mucolytic therapy prevents exacerbations. 
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6. CONCLUSIONS 
• A very detailed pharmaceutical care plan for patients with COPD has 
been developed. It should be understood as one of many parts of a 
comprehensive care plan which will be developed to be used in 
every patient with any chronic disease, rather than as a self-
contained project. 
• The developed care plan allows efficient task sharing and enables 
sharing of information between different health care professionals. 
• The Identification, selection and prioritisation of care issues is an 
individualised and subjective process. Extensive field-testing on a 
larger sample of patients is essential to ensure that care issues are 
incorporated into the plan at the correct level of detail. 
• There is a need for more research on treatment of COPD 
• The development of guidelines could ease the process of care plan 
development.  
• Theoretical and practical training are  necessary to train involved 
health care professionals in the correct use of the care plan 
• The care plan needs to be reviewed periodically to be kept up to 
date 
• The development and introduction of an electronic application for 
care planning would have many benefits. Paper versions of care 
plans such as developed during this research can be used for 
training and implemented in pilot schemes for electronic solutions. 
• The success of this pharmaceutical care plan will be judged by 
whether pharmacists extend their services and take on more 
responsibility. 
• The introduction of CMS will involve community pharmacists in 
Scotland to provide systematic care to a large number of patients 
 
Scotland provides a great example to the rest of Europe of the generation of 
efficient pharmaceutical care through the provision of a range of 
pharmaceutical care services which are backed up by constant research and 
development. Austria and other European countries could introduce a model 
similar to the Scottish one, and harness the particular skills and knowledge of 
pharmacists, as part of multidisciplinary teams, to provide pharmaceutical 
care to patients and thus make significant cost savings in times of a deficit 
national health insurance fund. 
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APPENDIX I 
 
CP-LTC 
F-RR 
List of suggestions for improvement of F-RR by Joanna Johnson 
CP-COPD-1 
CP-COPD-2 
CP-COPD-3 
Applicable version of CP-COPD-3 (black and white) 
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CP-LTC
  
Pharmaceutical Care of Patients with Long Term Conditions: Structured Assessment 
Number√ Name Disease Specific 
Monitoring Data 
              Standard Checks                                              Care 
                                                                                                √   issue      
Address √    
CHI (DoB) 
Smoker offered entry to cessation programme √  
  On disease self management plan√   10yr CHD risk ≥20% , Age>40 on aspirin 75mg √  
As above plus Diabetes & FH on Statin (MTD) √  Smoker√   
Past Smoker √    
Pack Years: √ 
Under cessation√    
Specialist  Advice √     Diet    Exercise     
 Smoking                                    
Past  MI  Date(s) √    
CVD Risk:    √                     %/10yr    
 
Lipid profile √    0n aspirin achieved a BP ≤ 150/90mm/Hg √  
Male ■ Female  Body Weight:  Height:   BMI    TC  ≥4 mmol/L  √       ■ Aspirin C/I, on Clopidogrel 75mg √  
Blood Pressure √     HDL <1 mmol/L   √      Stroke or TIA history on dipyridamole 200mg BD √  
mm Hg 
Dates 
       Sys/ Dia 
    
LDL ≥ 2mmol/L  √       TC≥4mmol/L on Statin unless  C/I √  
Patients with CHD Prescribed aspirin & statin √  PEFR Litres/hr √       Dates  
 
         Value 
    Diabetes Profile √    
Diabetes Risk:                       %/10yr 
C
H
D
 P
re
v
e
n
tio
n
 
   
GFR ml/min √     >50  30-50  <30  Hypertensive patient on treatment √  HbA1c  mmol/L:  9.9       date 11/10/09 
[Target <7mmol/L] Not prescribed combination of thiazide & b/blocker √  Cholesterol mmol/L  
Dates                      
                        Value 
    DEXA scan√ 
 
 
 Diabetes Complications √               
Neuropathic  pain√    ■ 
↑BP, ≤55yr, non-black on ACE inhibitor √  
Microalbuminuria √   ↑BP, >55yr, black on thiazide diuretics/ Ca Blocker √  
Last check dates: Eye 11/09  : Foot Heart failure patient on  ACE inhibitor -target dose √  
Known Allergies√   
 
High risk Medication user√   
 Corticosteroids  High dose inhaled steroids 
 Warfarin Digoxin   MTX      Others: Pulmonary Function  Diabetes + Angina, Hypertension on ACE inhibitor √  
Social Circumstances√   
H
y
p
e
rte
n
sio
n
 
Diabetes/CVD /Chronic Renal Failure  
blood pressure optimised (≤130/≤80) 
√  
 Lives alone  Housebound   Professional carer   Family carer AII antagonist indicated /use verified  √  
             Relevant Medical History Relevant Past Medication            Date BMI> 26(F)/27(M) kg/m2 on metformin √  
1    + BP Controlled, CVD≥20% on aspirin 75mg √  
2    
D
ia
b
e
te
s
 + CVD, TC<5, HDL<1 started on gemfibrozil √  
    Suitability of multiple inhaler prescribing ;  
3    on >2  inhalers   has  response confirmed 
√  
    On inhaled steroid  not > twice daily  √  
4    
COPD Prognosis index: 
Predicted 3yrs 
Mortality: 
Hospitalisations: 
Exacerbations:  
 
MRC DYPSNOEA SCORE /yr 
1     2      3      4     5 
  
 Mild  Moderate  Severe 
FEV1   ≥80%   50-79%          30-49% 
Oral steroid/6mths annual diabetes, BP & FRAX  √  
5    Stage      COPD                 Asthma FRAX assessment (if >800 mcg/day) √  
6    1 SABA COPD/asthma candidate for LABA √  
7    2 + Anticholinergic 
                +    Inhaled steroid 
L
u
n
g
  D
ise
a
s
e
 
Oral steroid/6mths is also on inhaled high dose √  
8    3 + LABA 
Current Medication 4 + Inhaled steroid 
        minus LABA   + Add on 
1  7  5 + Add on 
                          + Oral steroid 
2  8  Exacerbations:                in past yr 
[LABA indicated if >1] 
3  9  Vaccination√ 
4  10  √ Pneumonia    √   Influenza 
5  11  Obesity Profile 
6  12  Target  Wt:   √             68kg 
 Fracture Risk √ 
FRAX:         
               %/10yr        
 
Monitoring Notes 
 
 
 
 
Next 12 month review date: 
  
Care 
Issue STANDARD  TREATMENT VERIFICATIONS Output     (Initial
) 
1 Choice of medication/dose   Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive medication 
needs         CV Risk      Osteoporosis  
 Candidate for   statin  aspirin  
                             ACEI    ß Blocker 
Oral Biphosphonate  Ca & Vit D  
 
4 Assess patient comprehension  
and ability to administer medication 
 
 Inhaler Technique    
            Poor   0    1      2         3  Satisfactory 
 
INDIVIDUALISED CARE ISSUES 
 Date Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  
Treatment interruption/ Management of co-
morbidity) 
  Date Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify 1  
 
 
 4   
Action 
 
  
 
 
    
Output      
(Initial) 
      
Specify 2  
 
 
 5   
Action 
 
  
 
 
    
Output      
(Initial) 
      
Specify 3 
 
  6   
Action 
 
 
      
Output      
(Initial) 
      
  
 
 
INDIVIDUALISED CARE ISSUES 
 Week No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  
Treatment interruption/ Management of co-
morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
 12   
Action 
 
 
 
 
    
Output      
(Initial) 
7 
     
Specify  
 
 
 13   
Action 
 
 
 
 
    
Output      
(Initial) 
8 
     
Specify  
 
 
 14   
Action 
 
 
 
 
    
Output      
(Initial) 
9 
     
Specify  
 
 
 15   
Action 
 
 
 
 
    
Output      
(Initial) 
10 
 
     
Specify  
 
 
 16   
Action 
 
     
Output      
(Initial) 
11 
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F-RR 
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Respiratory Review 
            Date:   patient’s name:   DOB:    Age: 
   
Address:    GP: 
 
  Telephone number:      Ref no:   
ht:   wt:   BMI: 
  
Attended surgery □      House visit □       Phone review □       Other……………………………………..  
 
Exception coded from COPD review?:   Yes   □  No   □ 
 
Diagnosis 
Read code(s) recorded in records:  Asthma □   COPD □   Other □ 
Date of spirometry __________  Results (FEV1/FVC and FEV1% predicted): 
 
 
Mild (as per NICE guideline)  □  Moderate    □   Severe    □  
 
Recent chest x-ray      Date and result_____________________________   (For repeat CXR?)  
 
 
Other medical history: 
CHD  
Diabetes  
PVD  
CVA/ TIA  
Others: 
 
Previous year attendances for resp conditions only: 
 
Attendance Number in previous year 
At hospital outpatient  
At hospital inpatient stay  
At A & E  
At GP appointment  
At practice nurse appointment  
 
Number of exacerbation(s) in previous 2 years? 
 
1. Medication 
Number of medications on repeat (for any indication): 
 
Current respiratory prescription (Information from patient) 
Inhalers/ respiratory medication Actual dose knowledge, compliance, efficacy, ADRs, 
CIs, cost effectiveness ? 
   
   
   
   
   
 
Concordance issues      
None known □             Yes □    Reason, if known?  ______________________________ 
 
Referral to LTMS? 
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2. COPD review 
Date of review: 
 
Knowledge of COPD? 
 
 
Smoking status (information from patient) 
Never smoked            Ex smoker       Smoker   Motivated to quit ? Yes □   No □     
          Previous quit attempt(s) _______________________ 
 
Advice given Yes   No    Details……………………………………… 
 
MRC Grading (COPD)      
 MRC Grade 
Diagnosis of COPD but not restricted in usual daily activity 1 
Copes with daily activity but some difficulty keeping up with peers – especially 
hills and stairs 
2 
Restricted activity out-of-doors – unable to keep up with peers on the level 3 
Marked limitation in outdoor activity – stairs and inclines with great difficulty. Self 
caring indoors 
4 
Essentially housebound and requires some assistance in personal care 5 
              
    
 Yes No Not applicable ( give details) 
Satisfactory inhaler technique    
Discussed exacerbations    
Up to date flu vaccination    
Up to date pneumococcal vaccination    
 
 Yes No Details 
Pulmonary rehabilitation appropriate? 
 
   
LTOT/ ambulatory oxygen therapy 
assessment required? 
 
   
Depression? 
 
   
Onward referrals (pulmonary rehab, 
GP, LTMS)? 
 
   
 
Care issues (see attached referral): 
 
 
 
 
 
 
 
 
 
Follow up required □           Planned date for follow up _______________________ 
 
Time taken for review: 
 
Costs saved or incurred: 
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COPD review (follow up) 
Date _________       Attended surgery □      House visit □       Phone review □       Cancelled □       DNA □  
 
Changes to treatment: 
 
 
COPD control 
MRC Grading (COPD)      
 MRC Grade 
Diagnosis of COPD but not restricted in usual daily activity 1 
Copes with daily activity but some difficulty keeping up with peers – especially 
hills and stairs 
2 
Restricted activity out-of-doors – unable to keep up with peers on the level 3 
Marked limitation in outdoor activity – stairs and inclines with great difficulty. 
Self caring indoors 
4 
Essentially housebound and requires some assistance in personal care 5 
 
 
 
Assessment of response to therapy change (after minimum 1 month trial) 
 Yes No 
Has your treatment made a difference to you?   
Is your breathing easier in any way?   
Has your sleep improved?   
Can you do some thing now that you couldn’t do before or do the same things 
faster? 
  
Can you do the same things as before but are now less breathless when you do 
them? 
  
 
 
COPD management 
 Yes No Not applicable ( give details) 
Satisfactory inhaler technique    
Written self management plan    
Up to date flu vaccination    
Up to date pneumococcal vaccination    
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List of suggestions for improvement of F-RR by Joanna Johnson 
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How would I change the respiratory review form? 
 
Patient details 
 
Then a box with Height, weight, BMI, Blood pressure (enough room for the last 3 reported), 
Latest cholesterol, Cardiovascular Risk,  
 
U&E’s normal – Yes/No with a line for comments next to this. 
Urea and Electrolytes 
 
Smoking Status (currently on Pg 2) 
 
Other Medical History – just a box for details 
 
COPD details Ie Read code:     Asthma, COPD, Other 
 
Knowledge of COPD? 
 
Spirometry:   Practice/Outreach Spirometry 
Date: 
Fev1% Predicted: 
FEV1/FVC: 
Reversibility with salbutamol? 
 
Repeat spirometry needed?                                 Referral sent? 
 
Grade of COPD (as per NICE):  Mild/Moderate/Severe 
 
MRC Scale: Assessed by pharmacist/patient? – currently on page 2 
 
Number of exacerbations requiring Antibiotics and /or oral corticosteroids in the last year: 
 
Discussed exacerbations/self management issues _____________________ 
 
Seen by secondary care respiratory services?  If so, which ones?  Last seen? 
 
Current respiratory therapy – leave table but add on a column for inhaler technique for each of 
the meds. 
 
 
Concordance issues? 
 
Pulmonary Rehab Approp?   
 
Other issues ie Oxygen, Depression, further onward referrals:  DEXA scan, smoking cessation, 
Live Active, Dietitic Advice, outreach spirometry etc 
 
Care Issues: etc  
 
 
Follow up, time taken etc – all ok to stay as is. 
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CP-COPD-1 
 
 
 
 
 
  
Pharmaceutical Care of Patients with COPD: Structured Assessment Date 
Ref. Number: Name                Standard Checks                                             Care 
                                                                                                  issue      
Pregnancy  
Smoker offered entry to cessation programme  
Anxiety/Depression management  
Tel No:    
CHI (DoB) Age 
 
BMI<20: dietitian/ BMI>25: encourage  weight control  
10yr CHD risk ≥20% , Age>40 on aspirin 75mg  
As above plus Diabetes & FH on Statin (MTD)  
0n aspirin achieved a BP ≤ 150/90mm/Hg  
Address:  House visit 
 Phone review 
GP: 
Aspirin C/I, on Clopidogrel 75mg  
Stroke or TIA history on dipyridamole 200mg BD  
TC≥4mmol/L on Statin unless  C/I  
Next 12 month review date:                                         
 Follow up required:                    
 Phone review required: 
Ie Read code:    Asthma       COPD          
 Other:    
 Exception coded from COPD review 
 C
H
D
 P
re
v
e
n
tio
n
 
Patients with CHD Prescribed aspirin & statin  
Hypertensive patient on treatment  
Not prescribed combination of thiazide & b/blocker  
↑BP, ≤55yr, non-black on ACE inhibitor  
↑BP, >55yr, black on thiazide diuretics/ Ca Blocker  
Heart failure patient on  ACE inhibitor -target dose  
Smoker  
 Cannabis smoker  
 Past Smoker     
 Never smoked 
Pack Years:  
 Under cessation 
 Motivated to quit 
 prev. quit attempts:    
 
 On disease self management plan  
 Attended surgery 
 seen by secondary care respiratory 
services:            
Diabetes + Angina, Hypertension on ACE inhibitor  
 Male      Female weight:            unintentional wt loss height: BMI:                        
Social Circumstances:     Lives alone    Housebound     Professional carer    Family care 
H
y
p
e
r
te
n
sio
n
 
Diabetes/CVD /Chronic Renal Failure  
blood pressure optimised (≤130/≤80) 
 
Knowledge of COPD?    yes   no Specialist  Advice:  Diet    Exercise    Smoking    social service AII antagonist   indicated /    use verified   
GFR ml/min >50   30-50  <30 Urea and Electrolytes     normal     impaired: BMI> 26(F)/27(M) kg/m2 on metformin  
dates     + BP Controlled, CVD≥20% on aspirin 75mg  Blood 
Pressure mm HG     
D
ia
b
e
te
s 
+ CVD, TC<5, HDL<1 started on gemfibrozil  
dates     Asked about occupational dust or fume exposure  
Young onset or non-smoker: AAT-deficiency?  
PEFR  
 litres/hr 
 
    
Exacerbations & self management issues discussed  
Spirometry 
dates 
 practice    outreach     practice    outreach     practice    outreach    >1 exacerbation/year + FEV1 < 50%: LABA+inhaled 
Steroid (not > 2x daily)  
FEV1/FVC 
                 FEV1 
   Theophylline:  use verified,  plasmalevel 
monitored 
 
dates     Oral steroid/6mths annual diabetes, BP & DADS 
 
Cholesterol 
mmol/L     >65 yrs  + oral steroids: Osteoporosis prophylaxis  
1000 mcg beclometasone + risk factors: DADS referral  DXA scan 
(DADS) 
 Chest X-Ray  CT-scan  
Respiratory diagnosis unclear: refer patient  
Unexpected change in symptoms or MRC grade: 
referral to  spirometry   Chest X-ray 
 
LTOT/ ambulatory OT assessment  required  
High risk Medication user     MTX     
 Corticosteroids    High dose inhaled 
steroids   Warfarin Digoxin  Others: 
Known Allergies Monitoring notes: 
Ankle swelling: cor pulmonale?  
MRC>2: referral to pulmonary rehabilitation  Time taken for review:  Costs saved or incurred: 
 
 TC  ≥4 mmol/L       
 HDL <1 mmol/L  
 LDL ≥ 2mmol/L      
 
HbA1c                                                            mmol/L     
Diabetes Risk:                                 %/10yr 
 
CVD Risk:                                             %/10yr 
 
Fracture Risk  FRAX:         %/10yr 
 
Vaccinations (up to date?): 
Pneumonia      Influenza 
COPD profile 
Mild  Moderate  Severe 
 
MRC GRADE  (assessed by  
 pharmacist    patient): 
1     2      3      4     5 
 
Number of exacerbations requiring 
Antibiotics and /or oral corticosteroids 
in past year:   
 
Current COPD therapy: 
 SABA 
 +Tiotropium 
 +LABA 
 +Inhaled Steroid                    
 
 +LTOT 
 Oral Steroid                                        
  Theophylline                                    
 Mucolytic (carbocistein) 
 other: 
 
Reversibility with Salbutamol            
 no   yes     [more than 15% 
response in FEV1 suggests  asthma] 
 coexisting asthma 
C
O
P
D
 
On maximum doses +OT: if dyspnoeic: palliative care   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICATION 
 
clear 
benefit 
(after 1 
month) 
 
Relevant Medical History Relevant Past Medication date  
Current medication 
[• medication on repeat] 
Actual dose 
compliance, efficacy, 
ADRs, CIs, cost 
effectiveness 
yes no 
1    1      
2    2      
3    3      
4    4      
5    5      
6    6      
7    7      
8    8      
Past medication trials without clear benefit date 
Excluded medication: Reason for exclusion: 
Number of medications on repeat: Concordance issues: 
Care 
Issue 
STANDARD  TREATMENT VERIFICATIONS Output      
(Initial) 
1 Choice of medication/dose/ inhaler type  Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive medication 
needs         CV Risk      Osteoporosis  
 Candidate for   statin  aspirin  
                             ACEI    ß Blocker 
Oral Biphosphonate  Ca & Vit D  
 
4 Assess patient comprehension  
and ability to administer medication 
(SPACER?) 
 
 Inhaler Technique    
            Poor   0    1      2         3  Satisfactory 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDIVIDUALISED CARE ISSUES 
 Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  
Treatment interruption/ Management of co-
morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
   
Action 
 
 
 
 
   
Output      
(Initial) 
1 
  
6 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output      
(Initial) 
2 
  
7 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output      
(Initial) 
3 
  
8 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output      
(Initial) 
4 
 
  
9 
  
Specify  
 
 
   
Action 
 
    
Output      
(Initial) 
5 
  
10 
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CP-COPD-2 
  
Pharmaceutical Care of Patients with COPD: Structured Assessment Date 
Ref. Number: Name Standard Checks                                                                                         action          
                                                                                                                      care issue          
Tel. No. 
CHI (Dob) Age: 
MRC≥3 refer to pulmonary rehabilitation   
On  SAMA+LAMA switch to SABA   
On theophylline use verified,  on TDM   
Address: GP: 
≥1000 mcg beclometasone+ risk factors refer to DADS   
≥5mg prednisolone/3mths annual diabetes, BP + DADS   
>65 yrs  + oral steroids osteoporosis prophylaxis   
Hypertensive patient on treatment   
Ie Read code:     
COPD          
Asthma 
Other:   
 
Review: 
House visit 
Phone  
Clinic 
On disease self management plan  
Attended surgery 
Attended pulmonary rehabilitation 
Other secondary care services: 
↑BP, ≤ 55yr, non-black on ACE inhibitor   
↑BP, >55yr, black on thiazide diuretics/ Ca Blocker   
Diabetes/CVD /Chronic Renal Failure BP ≤130/≤80   
Beta blocker + COPD under specialist supervision   
High risk Medication user: Digoxin  
MTX    High dose inhaled Corticosteroid  
Warfarin  Corticosteroid    
Others: 
Known Allergies: 
CVD/↑BP/arrhythmia + β-agonist specialist supervision   
Female  Male Heart failure on ACE inhibitor -target dose   
weight  
Under cessation 
Desire to quit Patient with CVD prescribed aspirin & statin   
height  No. Cigs./day: 10yr CVD risk ≥20% , Age>40 on aspirin 75mg   
No. quit attempts:    + Diabetes & FH on Statin (MTD)   
BMI 
 
Social Circumstances:        
Lives alone  
Housebound     
Professional carer   
Family care 
Smoker  
Past Smoker     
Never smoked 
Dust/fumes   
   exposure Pack years: Warfarin + severe COPD decrease dose by 33%   
U&Es:    date:                    normal       impaired: Diabetes + Angina, Hypertension on ACE inhibitor   
GFR [ml/min] date:                    >50             50-30           <30 Diabetes + BMI> 26(F)/27(M) kg/m2 on metformin   
Glucose [mmol/l] date:                    <  6              6-7               >7    + CVD, TC<5, HDL<1 started on gemfibrozil   
Lipids [mmol/l] date:                    Chol ≥ 6     TC  ≥4          HDL <1     LDL ≥ 2 Respiratory diagnosis unclear refer  for clarification   
BP [Sys/Dia]    COPD onset<40yr, FH AAT-Deficiency refer to specialist   
dates    Smoker offered entry to cessation programme   
Spirometry practice   outreach practice outreach practice outreach Patient knowledge inadequate provide education   
dates    Symptom control inadequate adding of medication   
   On maximum medication refer for LTOT assessment   FEV1/FVC                
                          FEV1 
   
Clinical failure after all treatment options refer to 
specialist (palliative care) 
  
Reversibility [%]                                                                      Not coping at  home  refer for home care support   
MRC grade 1  2   3   4  5 1  2  3  4  5 1  2  3  4  5 Chronic sputum production  on carbocisteine   
assessed by pharmacist  patient pharmacist  patient pharmacist  patient HADS-D or HADS-A≥8 Anxiety/Depression management   
dates    Oedema presence (ankle swelling) on diuretics   
Chest X-Ray  CT-scan  On steroids educate about adverse effects   
date  date  BMI abnormal nutritional supplements, refer to dietician   
CVD risk (assign)  HADS-D & HADS-A   On self management but requires revision/support   
date  dates   Patient on LTOT on >15 hours/day   
DXA scan  Vaccinations Pneumonia Unexpected clinical worsening refer to specialist   
date  (up to date) Influenza 
COPD profile 
 
NICE: 
 Mild   [FEV1 ≥80%]   Severe [30-49%] 
 Moderate [50-79%]    Very Severe 
        [<30  or  <50 + RF] 
 
BODE index  
 
Patient’s age at initial COPD 
diagnosis 
 
 
Number of exacerbations 
requiring antibiotics or oral 
corticosteroids in past year 
 
 
 LTOT assessment         date: 
 
Comorbidities: 
 AAT-Deficiency 
 Asthma                             
 Cor pulmonale 
 CVD 
 Depression  
 Diabetes 
 Glaucoma 
 Hypertension 
 Osteoporosis  
 Other: 
 
Medication: 
 
 SABA or  SAMA 
 
 FEV1 ≥ 50%  FEV1 < 50% 
LABA  LAMA   
{LABA+IC} 
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA 
{LABA+IC} 
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
 Oral Steroid                    Mucolytic (carbocistein) 
 Theophylline                  Other:  
PaO2: SaO2: 
Pregnancy confirmed refer to specialist   
Next 12 month review date:   
 Follow up required:                           
 Phone review required:                            
Monitoring notes  
Time taken for review:  
Costs saved or incurred: 
  
 
MEDICATION 
 
Relevant Medical History Relevant Past Medication Date  
Current medication 
[• medication on repeat] 
 
Total number of medications on repeat: …… 
Actual 
Dose 
Comment 
1    1    
2    2    
3    3    
4    4    
5    5    
6    6    
7    7    
8    8    
9    9    
10    10    
11    
12    
Excluded medications: 
 
Trial: from - to Reason for exclusion: 
13    
Care 
Issue 
STANDARD  TREATMENT VERIFICATIONS Output      
(Initial) 
1 Choice of medication/dose/ delivery system  Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive medication 
needs          CV Risk     Osteoporosis  
Vaccinations: 
 Candidate for  statin  aspirin  ACEI     
ß Blocker  Ca & Vit D  Biphosphonate   
 
4 Assess patient comprehension  
and ability to administer medication             
Nebuliser use verified 
 Inhaler Technique    
            Poor   0    1      2      3  Satisfactory 
Candidate for  Spacer     Nebuliser 
 
  
  
INDIVIDUALISED CARE ISSUES 
 Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
1 
  
6 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
2 
  
7 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
3 
  
8 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
4 
 
  
9 
  
Specify  
 
 
   
Action 
 
    
Output        
(Initial) 
5 
  
10 
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CP-COPD-3
  
PHARMACEUTICAL CARE PLAN FOR PATIENTS WITH COPD 
CHI: Co-morbidities Name 
Tel. No. 
Dob Age: 
GP: 
 AAT-Deficiency 
      date of diagnosis: 
 
weight  
height  
 Allergies 
      date of diagnosis: 
 Address: 
Female   
Male 
BMI  
Ie Read code: 
COPD   Asthma 
Other:    Asthma 
      date of diagnosis: 
 
Social Circumstances:    
Lives alone               Housebound                
Professional carer  Family care 
On COPD self management plan        no     yes – date:                    
Attended pulmonary rehabilitation   no     yes  - date:                    
Other secondary care services:                                        date: 
 Cor pulmonale 
      date of diagnosis: 
 
U&Es date: normal  impaired: 
LFTs date: normal  impaired: 
 CVD 
      date of diagnosis: 
 
Lipids & Chol date: normal  impaired: 
GFR date: normal  impaired: 
 Depression 
      date of diagnosis: 
 
Glucose date: normal  impaired: 
BP [Sys/Dia]      
 Diabetes 
      date of diagnosis: 
 
dates      
Spirometry practice  outreach practice  outreach practice  outreach practice  outreach practice  outreach 
 Glaucoma 
      date of diagnosis: 
 
dates       Hypertension 
      date of diagnosis: 
 
FEV1/FVC                
                      FEV1 
     
Reversibility [%]      
 Osteoporosis 
      date of diagnosis: 
 
 None 
       
 
NICE 
classification 
of severity 
Mild    
Moderate  
Severe  
Very Severe  
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
 
MRC grade 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
dates      
 
assessed by pharmacist  patient pharmacist  patient pharmacist  patient pharmacist  patient pharmacist  patient 
CT-scan  Chest X-Ray  BODE index  
 Others: 
       
 
date  date  date  
LTOT assessm. PaO2:                       SaO2: DXA scan   
Vaccinations: Pneumonia no    yes-date:         
                             Influenza     no    yes-date:         
date   dates   
HADS-D     
Patient’s age at initial COPD diagnosis 
 
CVD risk 
(assign) 
 
HADS-A    
date  dates    
No. of exacerbations requiring ABs or oral 
corticosteroids in past year 
 
  
MEDICATION 
 
Relevant Medical History Relevant Past Medication Date  
Current medication 
[• medication on repeat] 
 
Total number of medications on repeat: …… 
Actual  
Dose 
Comment 
1    1    
2    2    
3    3    
4    4    
5    5    
6    6    
7    7    
8    8    
9    9    
10    10    
11    11    
12    12    
13    13    
14    14    
15    15    
16    
17    
18    
19    
Excluded medications: Trial: from - to Reason for exclusion: 
20    
High risk Medications:  Digoxin  MTX   High dose inhaled Corticosteroid  Warfarin   Corticosteroid    None  Others: 
  
Date: PHARMACEUTICAL CARE REVIEW 
 House visit   Phone    Clinic 
Care 
Issue 
STANDARD  TREATMENT VERIFICATIONS Output             
(Initial) 
1 Choice of medication/dose/ 
delivery system 
 Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive 
medication needs     CV Risk     
 Osteoporosis   Vaccinations 
 Candidate for  statin  aspirin   
ACEI     ß Blocker  Ca & Vit D 
Biphosphonate   
 
4 Assess patient comprehension  
and ability to administer medication          
Nebuliser use verified 
 Inhaler Technique    
  Poor   0    1      2      3  Satisfactory 
Candidate for  Spacer   Nebuliser 
 
Assessment of risk factors: 
Smoker Past Smoker  Never smoked 
Under cessation Occupational dust/fumes exposure: 
 
Pack years  
No. Cigs./day  
Currently using NRT 
             no     yes: 
 
 
Ready to quit Unwilling to quit 
 
Previous quit attempts  
Products used in failed attempts   
Monitoring notes  
 
COPD medication: 
 SABA or  SAMA 
 FEV1 ≥ 50%  FEV1 < 50% 
LABA LAMA 
{LABA+IC} 
 
LABA+LAMA 
    (if IC n/a) 
LAMA 
{LABA+IC} 
 
LABA+LAMA 
    (if IC n/a) 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
Oral Steroid       Theophylline         Mucolytic (carbocistein) 
Others: 
     
Time taken for review: Costs saved or incurred:  Follow up required:  Phone review required: Next 12 month review date: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard Checks                                                                                              action          
                                                                                                                  care issue          
MRC≥3 refer to pulmonary rehabilitation   
On regular SAMA ≥ 4/d switch to LAMA   
On theophylline use verified,  on TDM   
≥1000 mcg beclometasone+ risk factors refer to DADS   
≥5mg prednisolone/3mths annual diabetes, BP + DADS   
>65 yrs  + oral steroids osteoporosis prophylaxis   
Hypertensive patient on treatment   
↑BP, ≤ 55yr, non-black on ACE inhibitor   
↑BP, >55yr, black on thiazide diuretics/ Ca Blocker   
Diabetes/CVD /Chronic Renal Failure BP ≤130/≤80   
Beta blocker + COPD under specialist supervision   
CVD/↑BP/arrhythmia + β-agonist specialist supervision   
Heart failure on ACE inhibitor -target dose   
Patient with CVD prescribed aspirin & statin   
10yr CVD risk ≥20% , Age>40 on aspirin 75mg   
   + Diabetes & FH on Statin (MTD)   
Warfarin + severe COPD decrease dose by 33%   
Diabetes + Angina, Hypertension on ACE inhibitor   
Diabetes + BMI> 26(F)/27(M) kg/m2 on metformin   
   + CVD, TC<5, HDL<1 started on gemfibrozil   
Respiratory diagnosis unclear refer  for clarification   
COPD onset<40yr, FH AAT-Deficiency refer to specialist   
Smoker offered entry to cessation programme   
Patient knowledge inadequate provide education   
Symptom control inadequate adding of medication   
   On maximum medication refer for LTOT assessment   
Clinical failure after all treatment options refer to specialist    
Not coping at  home  refer for home care support   
Chronic sputum production  on carbocisteine   
HADS-D or HADS-A≥8 Anxiety/Depression management   
Oedema presence (ankle swelling) on diuretics   
On steroids educate about adverse effects   
BMI abnormal nutritional supplements, refer to dietician   
On self management but requires revision/support   
Patient on LTOT on >15 hours/day   
Unexpected clinical worsening refer to specialist   
Pregnancy confirmed refer to specialist   
  
INDIVIDUALISED CARE ISSUES 
 Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
1 
  
6 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
2 
  
7 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
3 
  
8 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
4 
 
  
9 
  
Specify  
 
 
   
Action 
 
    
Output         
(Initial) 
5 
  
10 
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Applicable version of CP-COPD-3 (black and white) 
 
  
PHARMACEUTICAL CARE PLAN FOR PATIENTS WITH COPD 
CHI: Co-morbidities Name 
Tel. No. 
Dob Age: 
GP: 
 AAT-Deficiency 
      date of diagnosis: 
 
weight  
height  
 Allergies 
      date of diagnosis: 
 Address: 
Female   
Male 
BMI  
Ie Read code: 
COPD   Asthma 
Other:    Asthma 
      date of diagnosis: 
 
Social Circumstances:    
Lives alone               Housebound                
Professional carer  Family care 
On COPD self management plan        no     yes – date:                    
Attended pulmonary rehabilitation   no     yes  - date:                    
Other secondary care services:                                        date: 
 Cor pulmonale 
      date of diagnosis: 
 
U&Es date: normal  impaired: 
LFTs date: normal  impaired: 
 CVD 
      date of diagnosis: 
 
Lipids & Chol date: normal  impaired: 
GFR date: normal  impaired: 
 Depression 
      date of diagnosis: 
 
Glucose date: normal  impaired: 
BP [Sys/Dia]      
 Diabetes 
      date of diagnosis: 
 
dates      
Spirometry practice  outreach practice  outreach practice  outreach practice  outreach practice  outreach 
 Glaucoma 
      date of diagnosis: 
 
dates       Hypertension 
      date of diagnosis: 
 
FEV1/FVC                
                      FEV1 
     
Reversibility [%]      
 Osteoporosis 
      date of diagnosis: 
 
 None 
       
 
NICE 
classification 
of severity 
Mild    
Moderate  
Severe  
Very Severe  
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
Mild    
Moderate  
Severe  
Very Severe 
 
MRC grade 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
dates      
 
assessed by pharmacist  patient pharmacist  patient pharmacist  patient pharmacist  patient pharmacist  patient 
CT-scan  Chest X-Ray  BODE index  
 Others: 
       
 
date  date  date  
LTOT assessm. PaO2:                       SaO2: DXA scan   
Vaccinations: Pneumonia no    yes-date:         
                             Influenza     no    yes-date:         
date   dates   
HADS-D     
Patient’s age at initial COPD diagnosis 
 
CVD risk 
(assign) 
 
HADS-A    
date  dates    
No. of exacerbations requiring ABs or oral 
corticosteroids in past year 
 
  
MEDICATION 
 
Relevant Medical History Relevant Past Medication Date  
Current medication 
[• medication on repeat] 
 
Total number of medications on repeat: …… 
Actual  
Dose 
Comment 
1    1    
2    2    
3    3    
4    4    
5    5    
6    6    
7    7    
8    8    
9    9    
10    10    
11    11    
12    12    
13    13    
14    14    
15    15    
16    
17    
18    
19    
Excluded medications: Trial: from - to Reason for exclusion: 
20    
High risk Medications:  Digoxin  MTX   High dose inhaled Corticosteroid  Warfarin   Corticosteroid    None  Others: 
  
Date: PHARMACEUTICAL CARE REVIEW 
 House visit   Phone    Clinic 
Care 
Issue 
STANDARD  TREATMENT VERIFICATIONS Output             
(Initial) 
1 Choice of medication/dose/ 
delivery system 
 Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive 
medication needs     CV Risk     
 Osteoporosis   Vaccinations 
 Candidate for  statin  aspirin   
ACEI     ß Blocker  Ca & Vit D 
Biphosphonate   
 
4 Assess patient comprehension  
and ability to administer medication          
Nebuliser use verified 
 Inhaler Technique    
  Poor   0    1      2      3  Satisfactory 
Candidate for  Spacer   Nebuliser 
 
Assessment of risk factors: 
Smoker Past Smoker  Never smoked 
Under cessation Occupational dust/fumes exposure: 
 
Pack years  
No. Cigs./day  
Currently using NRT 
             no     yes: 
 
 
Ready to quit Unwilling to quit 
 
Previous quit attempts  
Products used in failed attempts   
Monitoring notes  
 
COPD medication: 
 SABA or  SAMA 
 FEV1 ≥ 50%  FEV1 < 50% 
LABA LAMA 
{LABA+IC} 
 
LABA+LAMA 
    (if IC n/a) 
LAMA 
{LABA+IC} 
 
LABA+LAMA 
    (if IC n/a) 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
Oral Steroid       Theophylline         Mucolytic (carbocistein) 
Others: 
     
Time taken for review: Costs saved or incurred:  Follow up required:  Phone review required: Next 12 month review date: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard Checks                                                                                              action          
                                                                                                                  care issue          
MRC≥3 refer to pulmonary rehabilitation   
On regular SAMA ≥ 4/d switch to LAMA   
On theophylline use verified,  on TDM   
≥1000 mcg beclometasone+ risk factors refer to DADS   
≥5mg prednisolone/3mths annual diabetes, BP + DADS   
>65 yrs  + oral steroids osteoporosis prophylaxis   
Hypertensive patient on treatment   
↑BP, ≤ 55yr, non-black on ACE inhibitor   
↑BP, >55yr, black on thiazide diuretics/ Ca Blocker   
Diabetes/CVD /Chronic Renal Failure BP ≤130/≤80   
Beta blocker + COPD under specialist supervision   
CVD/↑BP/arrhythmia + β-agonist specialist supervision   
Heart failure on ACE inhibitor -target dose   
Patient with CVD prescribed aspirin & statin   
10yr CVD risk ≥20% , Age>40 on aspirin 75mg   
   + Diabetes & FH on Statin (MTD)   
Warfarin + severe COPD decrease dose by 33%   
Diabetes + Angina, Hypertension on ACE inhibitor   
Diabetes + BMI> 26(F)/27(M) kg/m2 on metformin   
   + CVD, TC<5, HDL<1 started on gemfibrozil   
Respiratory diagnosis unclear refer  for clarification   
COPD onset<40yr, FH AAT-Deficiency refer to specialist   
Smoker offered entry to cessation programme   
Patient knowledge inadequate provide education   
Symptom control inadequate adding of medication   
   On maximum medication refer for LTOT assessment   
Clinical failure after all treatment options refer to specialist    
Not coping at  home  refer for home care support   
Chronic sputum production  on carbocisteine   
HADS-D or HADS-A≥8 Anxiety/Depression management   
Oedema presence (ankle swelling) on diuretics   
On steroids educate about adverse effects   
BMI abnormal nutritional supplements, refer to dietician   
On self management but requires revision/support   
Patient on LTOT on >15 hours/day   
Unexpected clinical worsening refer to specialist   
Pregnancy confirmed refer to specialist   
  
INDIVIDUALISED CARE ISSUES 
 Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
1 
  
6 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
2 
  
7 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
3 
  
8 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
4 
 
  
9 
  
Specify  
 
 
   
Action 
 
    
Output         
(Initial) 
5 
  
10 
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Email containing feedback by Joanna Johnson 
Attachment of email by Joanna Johnson 
Email containing feedback by Lynn Alexander 
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Applicable version of CP-COPD-2, as submitted to 
Pharmacists 
  
Pharmaceutical Care of Patients with COPD: Structured Assessment Date 
Ref. Number: Name Standard Checks                                                                                         action          
                                                                                                                      care issue          
Tel. No. 
CHI (Dob) Age: 
MRC≥3 refer to pulmonary rehabilitation   
On  SAMA+LAMA switch to SABA   
On theophylline use verified,  on TDM   
Address: GP: 
≥1000 mcg beclometasone+ risk factors refer to DADS   
≥5mg prednisolone/3mths annual diabetes, BP + DADS   
>65 yrs  + oral steroids osteoporosis prophylaxis   
Hypertensive patient on treatment   
Ie Read code:     
COPD          
Asthma 
Other:   
 
Review: 
House visit 
Phone  
Clinic 
On disease self management plan  
Attended surgery 
Attended pulmonary rehabilitation 
Other secondary care services: 
↑BP, ≤ 55yr, non-black on ACE inhibitor   
↑BP, >55yr, black on thiazide diuretics/ Ca Blocker   
Diabetes/CVD /Chronic Renal Failure BP ≤130/≤80   
Beta blocker + COPD under specialist supervision   
High risk Medication user: Digoxin  
MTX    High dose inhaled Corticosteroid  
Warfarin  Corticosteroid    
Others: 
Known Allergies: 
CVD/↑BP/arrhythmia + β-agonist specialist supervision   
Female  Male Heart failure on ACE inhibitor -target dose   
weight  
Under cessation 
Desire to quit Patient with CVD prescribed aspirin & statin   
height  No. Cigs./day: 10yr CVD risk ≥20% , Age>40 on aspirin 75mg   
No. quit attempts:    + Diabetes & FH on Statin (MTD)   
BMI 
 
Social Circumstances:        
Lives alone  
Housebound     
Professional carer   
Family care 
Smoker  
Past Smoker     
Never smoked 
Dust/fumes   
   exposure Pack years: Warfarin + severe COPD decrease dose by 33%   
U&Es:    date:                    normal       impaired: Diabetes + Angina, Hypertension on ACE inhibitor   
GFR [ml/min] date:                    >50             50-30           <30 Diabetes + BMI> 26(F)/27(M) kg/m2 on metformin   
Glucose [mmol/l] date:                    <  6              6-7               >7    + CVD, TC<5, HDL<1 started on gemfibrozil   
Lipids [mmol/l] date:                    Chol ≥ 6     TC  ≥4          HDL <1     LDL ≥ 2 Respiratory diagnosis unclear refer  for clarification   
BP [Sys/Dia]    COPD onset<40yr, FH AAT-Deficiency refer to specialist   
dates    Smoker offered entry to cessation programme   
Spirometry practice   outreach practice outreach practice outreach Patient knowledge inadequate provide education   
dates    Symptom control inadequate adding of medication   
   On maximum medication refer for LTOT assessment   FEV1/FVC                
                          FEV1 
   
Clinical failure after all treatment options refer to 
specialist (palliative care) 
  
Reversibility [%]                                                                      Not coping at  home  refer for home care support   
MRC grade 1  2   3   4  5 1  2  3  4  5 1  2  3  4  5 Chronic sputum production  on carbocisteine   
assessed by pharmacist  patient pharmacist  patient pharmacist  patient HADS-D or HADS-A≥8 Anxiety/Depression management   
dates    Oedema presence (ankle swelling) on diuretics   
Chest X-Ray  CT-scan  On steroids educate about adverse effects   
date  date  BMI abnormal nutritional supplements, refer to dietician   
CVD risk (assign)  HADS-D & HADS-A   On self management but requires revision/support   
date  dates   Patient on LTOT on >15 hours/day   
DXA scan  Vaccinations Pneumonia Unexpected clinical worsening refer to specialist   
date  (up to date) Influenza 
COPD profile 
 
NICE: 
 Mild   [FEV1 ≥80%]   Severe [30-49%] 
 Moderate [50-79%]    Very Severe 
        [<30  or  <50 + RF] 
 
BODE index  
 
Patient’s age at initial COPD 
diagnosis 
 
 
Number of exacerbations 
requiring antibiotics or oral 
corticosteroids in past year 
 
 
 LTOT assessment         date: 
 
Comorbidities: 
 AAT-Deficiency 
 Asthma                             
 Cor pulmonale 
 CVD 
 Depression  
 Diabetes 
 Glaucoma 
 Hypertension 
 Osteoporosis  
 Other: 
 
Medication: 
 
 SABA or  SAMA 
 
 FEV1 ≥ 50%  FEV1 < 50% 
LABA  LAMA   
{LABA+IC} 
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA 
{LABA+IC} 
 
LABA+ 
    LAMA   
    (if IC n/a) 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
LAMA + 
   {LABA+IC} 
 Oral Steroid                    Mucolytic (carbocistein) 
 Theophylline                  Other:  
PaO2: SaO2: 
Pregnancy confirmed refer to specialist   
Next 12 month review date:   
 Follow up required:                           
 Phone review required:                            
Monitoring notes  
Time taken for review:  
Costs saved or incurred: 
  
 
MEDICATION 
 
Relevant Medical History Relevant Past Medication Date  
Current medication 
[• medication on repeat] 
 
Total number of medications on repeat: …… 
Actual 
Dose 
Comment 
1    1    
2    2    
3    3    
4    4    
5    5    
6    6    
7    7    
8    8    
9    9    
10    10    
11    
12    
Excluded medications: 
 
Trial: from - to Reason for exclusion: 
13    
Care 
Issue 
STANDARD  TREATMENT VERIFICATIONS Output      
(Initial) 
1 Choice of medication/dose/ delivery system  Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
2 Clinical/Laboratory monitoring    Meets guideline recommendations 
 Identified exception 
 Identified special precaution 
 
3 Check for unmet preventive medication 
needs          CV Risk     Osteoporosis  
Vaccinations: 
 Candidate for  statin  aspirin  ACEI     
ß Blocker  Ca & Vit D  Biphosphonate   
 
4 Assess patient comprehension  
and ability to administer medication             
Nebuliser use verified 
 Inhaler Technique    
            Poor   0    1      2      3  Satisfactory 
Candidate for  Spacer     Nebuliser 
 
  
  
INDIVIDUALISED CARE ISSUES 
 Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Week 
No   
+ Date 
Patient Education 
 Documentation 
Additional Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment 
interruption/ Management of co-morbidity) 
Specify  
 
 
   
Action 
 
 
 
 
   
Output         
(Initial) 
1 
  
6 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
2 
  
7 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
3 
  
8 
  
Specify  
 
 
   
Action 
 
 
 
 
   
Output        
(Initial) 
4 
 
  
9 
  
Specify  
 
 
   
Action 
 
    
Output        
(Initial) 
5 
  
10 
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Email containing feedback by Joanna Johnson 
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Hi there, 
 
I have attached my comments re the care plan - reading my big long list looks like I 
have pulled it to pieces however I really think you have done a great job pulling all 
this information together.  The changes I have suggested will make the process of 
care planning simpler and more logical as for most of us, this is done in a mad rush. 
 
I have just written the list of comments in a mad rush so I hope they make sense - 
please let me know if you would like me to try using any ammended versions that you 
produce and if my comments aren't clear. 
 
Jo 
 
Joanna Johnson 
COPD Support Pharmacist 
Pharmacy & Prescribing Support Unit 
NHS Greater Glasgow & Clyde 
Queens Park House, Langside Road 
Glasgow G42 9TY 
0141 201 5333 
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Attachment of email by Joanna Johnson 
 
 
 
 
 
 - 114 - 
Comments for Magdalena, 
 
1. The font on the first page is just too small to be easily workable.  I am undecided 
about whether the Standard Checks is necessary to have.  My recommendation 
would be that you have a ‘reminder page’ at the back containing this information 
that people can use if they want or else just not print it off.  This list would really only 
be necessary to pharmacists very new to running clinics so I do think a reminder 
sheet would be helpful for them.  It also gives you a lot more space to increase the 
font size of the other information.  I haven’t had a chance to check this section for 
correctness but the line on SAMA & LAMA switch to SABA is not correct. 
2. I think you need two separate boxes to record CHI and DOB. 
3. The box where you ask about self management plans I would move to after you have 
recorded MRC grade and change it to look something like: 
COPD self management plan      YES/NO 
Attended Pulmonary Rehabilitation          YES/NO 
  If yes, when? 
       Appropriate for referral to Pulm Rehab YES/NO 
        Other secondary care services  YES/NO 
  If yes, details 
 I am not convinced that surgery is necessary to have on. 
4. GFR, Glucose, Lipids:  I would just leave the boxes blank for the pharmacist to write 
the level in themselves. 
5. High risk medications:  I think that if you are going to include this box it should be on 
the second page. 
6. Smoking: 
a. The third box I would change 
Pack Years: 
Currently using NRT O 
Ready to quit  O 
Unwilling to quit O 
No of quit attempts: 
Products used in failed attempts: 
7. The severity scale needs to go immediately underneath the spirometry details. 
8. There needs to be much more space to enter details of co-morbidities and I think this 
needs to go further up the page as this is an essential piece of information to get. 
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Email containing feedback by Lynn Alexander 
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Hi Magdelena, 
 
Yes i did try this out, thanks for reminding me! (Friday seems like ages ago!) 
 
I think it's really good. A couple of things that confused me - the Ref number at the 
top, what's that for? Is it for anonymising patients therefore leaving out the CHI 
number and name/address? 
 
Can the "high risk medication user" be changed to "High risk Medications" and add a 
box for "none" as an empty box could sometimes be an oversight so adding a "none" 
rules that out. 
 
Also the wee box that starts "on disease management plan" Think this is good stuff to 
have in but it did confuse me a little, why is attended surgery in there? Is it "Attended 
clinic in surgery" or "Attended yearly review in surgery"? Should the pulmonary rehab 
perhaps be expanded to: Referred to pulm rehab, Attended pulm rehab, Completed 
pulm rehab? Should there also be "Attends 2ndary care clinic" in there as well as 
"other secondary care services"? Maybe dates would be useeful here instead of a 
tickbox? 
 
LFTs need to be included in the investigations part. 
 
Also under "co-morbidities" can there be a box for "none" as unusually I did have one 
patient with no co-morbidities on Friday! 
 
Really useful to have so well done, Hope these suggestions help. Let me know if 
there's anything else I can do, 
 
 
Lynn Alexander MRPharmS 
Prescribing Support Pharmacist 
East Renfrewshire CHCP 
07810054227 
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Curriculum vitae (Lebenslauf) in German 
Curriculum vitae in English 
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Curriculum vitae (Lebenslauf) in German 
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LEBENSLAUF 
 
Magdalena Hellauer 
03.02.1985 
Michaelistr. 20 
5280 Braunau 
Austria 
 
 
Schulbildung: 
 
1991 - 1995   Volksschule Braunau Neustadt 
 
1995 - 1999   Bundesrealgymnasium Braunau 
 
1999 - 2004   HTL Braunau, Austria  
  
• Programmiersprachen : Java, C++, Java Script, PHP, MySQL, 
HTML 
• Digitale Bildbarbeitung und Videoschnitt 
• Cisco Network Administrator Zertifikat 
• Matura mit Auszeichnung 
 
 
10/2004  Ergänzungsmatura Biologie am BORG Ried 
    
• Spezialisierung: „Homöopathie kritisch betrachtet“ 
 
 
10/2004  Beginn des Diplomstudiums Pharmazie an der Universität Wien  
 
01/2008- 06/2008 Erasmus Auslandssemester an der Universität Helsinki, Finnland: 
 
• Spezialisierung auf Patientenorientierte Pharmazie  
• Mitarbeit in einer Forschungsgruppe  
 („Polymorphism screening of Betulin“) 
 
 
03/2010- 09/2010 Auslandssemester an der University of Strathclyde, Glasgow,  
   Vereinigtes Königreich: 
 
• Durchführung der Forschungsarbeiten für die Diplomarbeit am 
Strathclyde Institute of Pharmacy and Biomedical Sciences 
 
 
09/2010  Diplomprüfung Pharmazie 
    
• Titel der Diplomarbeit: ‘A Pharmaceutical Care Plan for the 
management of chronic obstructive pulmonary disease (COPD): 
development and validation for use in the community’ 
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Berufserfahrung: 
 
 
01.10.2005 - 30.09.2010  Angestelle für administrative Tätigkeiten   
     Dürr KG, Tribuswinkel 
 
01.10.2007 - 28.02.2010  Tutorin für Mikrobiologie Labor 
     Department für Pharmakologie und Toxikologie,  
     Universität Wien 
 
01.07.2007- 31.08.2007  Praktikum       
     Baxter BioScience, LCM Coagulation, Wien 
 
01.09.2006 - 30.09.2006  Praktikum 
     Anstaltsapotheke Braunau 
      
01.07.2004 - 30.09.2004  Praktikum 
     Wacker Chemie, Burghausen, Deutschland 
 
01.08.2002 - 31.08.2002  Praktikum 
01.07.2001 - 31.07.2001  Austrian Aerospace, Wien 
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Curriculum vitae in English 
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CURRICULUM VITAE 
 
Magdalena Hellauer 
03.02.1985 
Michaelistr. 20 
5280 Braunau 
Austria 
 
 
Education: 
 
1991 - 1995   Primary school Braunau Neustadt, Austria 
 
1995 - 1999   Grammar school Braunau, Austria 
 
1999 - 2004   HTL Braunau, Austria  
   (College for Programming, Engineering and Mediadesign) 
  
• Programming languages : Java, C++, Java Script, PHP, MySQL, 
HTML 
• Digital image and video processing 
• Cisco Network Administrator Certification 
• ‘Matura’ with distinction 
 
 
10/2004  Additional ‘Matura’ for Biology at BORG Ried, Austria  
   (Grammar school)    
 
• Specialistation: ‘A critical overview of Homoeopathy’ 
 
 
10/2004  Beginning of Pharmacy studies at University of Vienna, Austria 
 
01/2008- 06/2008 Exchange semester at University of Helsinki, Finland: 
 
• Specialiation in pharmaceutical care 
• Laboratory experience within a research group    
 (Polymorphism screening of Betulin) 
 
 
03/2010- 09/2010 Exchange semester at University of Strathclyde, Glasgow, UK: 
 
• Conduction of research for the master thesis at the   
 Strathclyde Institute of Pharmacy and Biomedical Sciences 
 
 
09/2010  Graduation as MSc of Pharmacy at University of Vienna 
    
• Title of master thesis: ‘A Pharmaceutical Care Plan for the 
management of chronic obstructive pulmonary disease (COPD): 
development and validation for use in the community’ 
 - 123 - 
Employment Experience: 
 
 
01.10.2005 - 30.09.2010  Quality- and Process Management Administrator  
     Dürr KG, Tribuswinkel, Austria 
 
01.10.2007 - 28.02.2010  Tutor for Microbiology lab course 
     University of Vienna, Austria 
 
01.07.2007- 31.08.2007  Internship, Administration     
     Baxter BioScience, LCM Coagulation, Vienna, Austria 
 
01.09.2006 - 30.09.2006  Internship, Pharmacy Technician    
     Hospital Pharmacy Braunau, Austria 
      
01.07.2004 - 30.09.2004  Internship, Product Quality Assessor 
     Wacker Chemie, Burghausen, Germany 
 
01.08.2002 - 31.08.2002  Internship, Programmer 
01.07.2001 - 31.07.2001  Austrian Aerospace, Vienna, Austria 
 
